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1. INTRODUCTION 
Tuberculosis (TB) is an airborne infectious disease caused by Mycobacterium 
tuberculosis. The common source of the disease is an infectious person who, by 
sharing common air space, infects the other one. The most effective way to stop 
the spread of TB is early identification of the infectious cases and immediate 
treatment. However, the progression from TB infection to development of the 
disease and further to cure or death depends on the etiologic agent, host orga-
nism, clinical management and socio-economic factors (1), which all should be 
counted in the management of TB. 
In 2011, the World Health Organization (WHO) estimated the incidence as 
8.7 million cases of TB globally. During 2011, approximately 1.4 million 
people died of TB (2). Most of the cases occurred in the WHO regions of 
South-East Asia, the Western Pacific and African Region (2). It is recognised 
that the immunodeficiency virus (HIV) is the major factor fuelling the TB 
epidemic. Thus, the HIV and TB co-infected patients accounted for 13% of all 
TB cases in 2011, the highest proportion of them estimated to be among the 
residents of the WHO African Region. During the same year, 0.99 million 
deaths occurred among HIV-negative cases of TB and an additional 0.43 mil-
lion deaths among people with an HIV infection (2). 
During the last few decades, drug-resistant TB, a man-made phenomenon, 
has increased significantly. Annually, around 630,000 patients fall sick with 
multidrug-resistant TB (MDR-TB) worldwide (2). MDR-TB is defined as TB 
caused by M. tuberculosis resistant in vitro to isoniazid (INH) and rifampicin 
(RMP). MDR-TB takes longer to treat than non-MDR-TB and necessitates use 
of expensive and less-effective second-line anti-TB drugs (SLDs) (3). In 2011, 
it was estimated that 3.7% of new TB cases and 20% of retreatment cases had 
MDR-TB (2). Of the 27 high-MDR-TB-prevalence countries, i.e. those count-
ries where the proportion of MDR-TB among never previously treated cases 
exceeds 6.5%, 15 were in the WHO European Region, Estonia being one of 
them (2). 
Misuse or mismanagement of SLDs may result in development of strains of 
extensively drug-resistant TB (XDR-TB), which is in vitro resistant to INH and 
RMP, a fluoroquinolone, and to at least one of the three injectable SLDs 
(amikacin (AMK), capreomycin (CM), or kanamycin (KM)) (3). By the end of 
2011 at least one case of XDR-TB was reported by 84 countries worldwide. It 
was estimated that approximately 9.0% of all MDR-TB cases have XDR-TB, 
equivalent to 58,500 cases (4). 
After a rapid diagnosis of TB or M/XDR-TB, an effective treatment bringing 
long-term cure should be initiated as soon as possible to stop the transmission of 
the infection. The Stop TB a scale-up intervention plan for the period 
20112015 foresees at least a 90% treatment success rate among drug-
susceptible TB and ≥75% among MDR-TB cases (5). In cases of the non-HIV-
infected drug-sensitive TB patients, it is possible to achieve 9799% treatment 
success rates with an average disease recurrence of less than 5% (6). In 2010, 
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the global treatment success among the new smear positive TB cases was 87%, 
whereas in the African Region, where the proportion of persons with TB/HIV 
co-infection was the highest, reached 82%. Meanwhile, the treatment success 
among new smear positive cases in the WHO European Region, where elevated 
MDR-TB rates are a problem, was only 67% (2). 
It is known that treatment success is considerably lower among the drug-
resistant cases; thus, for the MDR-TB patients the global treatment success was 
48% and for XDR-TB patients 33% (2). The particularly deadly liaison of 
XDR-TB and HIV infection was demonstrated in a study from KwaZulu Natal, 
South Africa, where 52 of 53 (98.1%) patients with XDR-TB and HIV co-
infection died (7). 
Provided the treatment is effective, TB recurrence has been shown to be 
moderate in cases of drug-sensitive TB. According to a systematic review of 16 
studies (8), the disease recurrence after successful treatment ranged from 
014%. However, there is a significantly higher risk of TB recurrence and 
mortality among TB and HIV co-infected persons (9). Little is known about the 
recurrence rate among MDR-TB patients after successful treatment (10) and 
none of the studies is of a countrywide-design.  
It is acknowledged that TB, HIV, smoking and alcohol abuse are closely 
related, fuelling epidemics exacerbated by interacting factors (11, 12). HIV, 
smoking and alcohol abuse are risk factors for TB infection, disease and 
mortality. All of the four mentioned pose a major public health challenge, as 
well as torment at the individual level. 
In Estonia, the problem of TB, but also of M/XDR-TB, escalated after the 
sharp social and economic changes in the 1990’s, i.e. the break-up of the Soviet 
Union. In 1998 the first survey of drug-resistance was carried out in Estonia and 
a proportion of MDR-TB as high as 10.2% of the new cases was found (13). To 
address the increasing TB incidence and prevent further escalation of M/XDR-
TB, the Estonian National TB Control Programme (NTP) was established in 
1998.  
The present series of studies was undertaken to evaluate the impact of 
M/XDR-TB on TB incidence, disease recurrence and mortality and to identify 
the causes of death of TB and M/XDR-TB patients in Estonia and subsequently 
identify ways to effectively decrease TB and M/XDR-TB incidence and to 
increase the survival rate of individual TB patients.  
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2. REVIEW OF THE LITERATURE 
The review of the literature touches upon the origin and definitions of TB, the 
Stop TB Strategy and summarises TB and M/XDR-TB occurrence globally and 
in Estonia. Incidence, treatment, disease recurrence and mortality of TB and 
drug resistant TB are dealt with. 
 
 
 2.1. Origin and definition of TB, MDR-TB and XDR-TB 
The causative agent of TB, M. tuberculosis, is as old as 3 million years (14). 
The oldest known human remains showing signs of TB are 9,000 years old (15). 
It has been estimated that in the early 19th century, 30% of all deaths under  
50 years of age in Europe could have been attributed to TB (16). Disappoin-
tingly, only as late as in January 1944, the discovery of the anti-TB drug 
streptomycin (STM) was announced (17). A few months before, in March 1943, 
a proposal to manufacture a para-amino salt of aspirin as an anti-TB agent was 
presented by Lehmann in Sweden (17). The first treatment with para-amino 
salicylic acid (PAS) was initiated in October and with STM in November 1944 
(17). With the introduction of anti-TB drugs, a hope appeared to win over the 
disease. Meanwhile, already in 1948, in trials in Great Britain (18) and later in 
the United States (19), it was shown that resistance to STM had emerged. 
Putting this into context with our present knowledge, the resistance to STM was 
most probably due to monotherapy of patients with this agent, novel at that 
time. 
The spontaneous occurrence of drug-resistant mutants among wild strains of 
M. tuberculosis has been well described (20, 21). Nonetheless, it is considered 
that the drug resistance is primarily a man-made phenomenon, i.e. caused by 
inadequate or poorly administered treatment regimens that enable drug resis-
tance to develop (3). 
The hypothesis of how the resistance to anti-TB drugs may develop was 
introduced by Mitchison (22). In his paper, Mitchison described three modes of 
action of anti-TB drugs:  
1) Prevention of drug-resistance  a drug of high activity is able to prevent 
growth of the entire bacterial population in the lesions throughout chemo-
therapy. A drug of low activity fails to be as suppressive and may allow 
growth of mutant bacilli;  
2) Early bactericidal activity  the ability of anti-TB drugs to kill most of the 
live bacilli during first two days of treatment. By doing so, the number of 
bacteria and therefore, the number of possible mutations, will decrease;  
3) Sterilizing activity  ability to kill all of the bacilli in the lesions as rapidly 
as possible. Sterilizing activity measures the speed with which the last few 
viable bacilli are killed.  
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In 1948, it was demonstrated that combined chemotherapy, i.e., using more than 
one drug simultaneously, could appreciably prevent the emergence of drug-
resistance (23). Furthermore, it was deemed necessary to ensure that all pre-
scribed doses of combination therapy were actually taken by the patients. In 
1960, the British Medical Research Council developed a fully supervised 
chemotherapy routine to ensure patient adherence to the prescribed treatment 
regimen. Over twenty years passed before the International Union against 
Tuberculosis and Lung Disease gradually implemented fully supervised chemo-
therapy under programmatic conditions in Tanzania and other African countries 
in the 1980s (24). Meanwhile, more drugs were introduced for treatment of TB 
and, unfortunately, further resistance developed. 
In 1998, Mitchison (25) went on describing four mechanisms of develop-
ment of resistance in case of poor compliance during short course chemo-
therapy. The mechanisms were: 
1) Bactericidal effect during initial killing – resistance emerging during first 
days of interrupted treatment due to selection of spontaneously occurred 
mutations; 
2) Mono-therapy during sterilisation of special populations – selection of 
resistant bacilli from special populations of semi-dormant organisms, with 
only one anti-TB drug having action in them;  
3) Sub-inhibitory drug concentrations during re-growth – in this case the resis-
tant bacilli will grow faster than sensitive;  
4) Bacteriopausal effects during re-growth  the selective growth of drug-
resistant mutants during the period, when no drugs are taken.  
 
It is known that in case the bacilli are resistant to the two most potent first-line 
anti-TB drugs (FLDs), INH and RMP, the patient is very difficult to cure and this 
form of TB is demarcated by a special name, MDR-TB. Since the 1990’s highly 
or extremely resistant bacilli, resistant to six or more drugs, have been reported 
(2628). In those cases, the treatment success was worse (56.0%) (27) than in the 
case of drug-sensitive TB (9799%) (6), and even worse than that of MDR-TB 
(66.270.2%) (29). In 2005, a provisional definition of extensive drug resistance 
was first introduced (30). In 2006 WHO convened and revised the provisional 
XDR-TB case definition (31). The current definition of XDR-TB states that it is a 
form of TB in which bacilli is resistant in vitro to INH, RMP, a fluoroquinolone 
and to at least one of three injectable SLDs (AMK, CM, or KM). 
The increasing number of reports of high prevalence of drug resistance and 
lack of novel anti-TB drugs has given rise to pessimistic thoughts on the future 
of TB control. In that context, a question has been posed; exactly how trans-
mittable are these resistant strains compared to drug-sensitive strains. In 2009, 
Borrell and Ganneux (32) reviewed available studies on infectiousness, repro-
ductive fitness and evolution of drug-resistant M. tuberculosis. They concluded 
that the transmissibility was variable, being from 10 times more (33) to 10 times 
less (34) transmittable, and could depend on two major aspects:  
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1) Relative fitness compared to the drug-sensitive strains – likelihood to sur-
vive and reproduce. This could be varying based on the strain’s genetic 
background; 
2) “Fitness cost” – a reduced growth of resistant strains due to the impact of 
the mutations on the normal function of the genes. Nevertheless, even if the 
drug-resistant strains are of decreased relative fitness due to the occurred 
mutations, in some cases, the drug-resistant strains, after initial reduction of 
fitness, undergo compensatory evolution and regain their fitness. 
 
Based on these theories, certain mathematical models lead to a possibility that, 
given time, a fit MDR-TB strain may nonetheless replace the drug-sensitive 
strain (35). Other models conclude that the future spread of drug-resistant 
strains is not that alarming because the resistance is often associated with 
reduction in bacterial fitness (36). Dye (37) has brought forward the hypothesis 
of severe and benign epidemics. A severe epidemic, illustrated by an example of 
Russia during the period 19992005, is characterised by a self-sustaining 
epidemic of drug-resistant strains. Dye et al. (36) reviewed the trends of MDR-
TB incidence rates among new cases in 10 high-MDR-TB-countries, including 
Estonia. They concluded that in those settings the reproduction of INH-resistant 
and MDR-TB strains was less than that of the sensitive strains, representing a 
benign TB epidemic. Furthermore, as resistant strains are likely to occur due to 
mutations developing within the sensitive strains and resistant mutants are less 
fit than the sensitive ones, the production of resistant strains could be decreased 
by stopping the spread of regular TB (37). This finding led to the conclusion 
that the current diagnostic and treatment strategies can still result in elimination 
of MDR-TB. There is, however, a contradiction to the hypothesis of a benign 
epidemic in Estonia, as Krüüner et al. (38) found that the prevailing TB strain 
spreading in Estonia belongs to the Beijing genotype family with a high 
probability (11.5%) of being MDR. More importantly, this strain was found to 
be at least as transmissible as other strains (32, 38). It is not known which type 
of TB and MDR-TB epidemic is prevailing in Estonia, therefore one of the aims 
of the current study was to assess the notification rates of both TB and MDR-
TB in Estonia.  
 
 
2.2. Occurrence of TB and M/XDR-TB 
The WHO has been collecting TB case notification data since 1997 (39) from 
all its Member States, other countries and territories in order to assess the 
burden of disease and its trend worldwide. In 2012, a total of 182 out of 194 
Member States reported TB-related data to the WHO. In Estonia the TB data 
have been collected throughout the last century but aligned to the international 
recommendations since 1998.  
 
 
 14
2.2.1. Global occurrence of TB and M/XDR-TB 
In 2011, there were an estimated 8.7 million incident cases of TB (range 
8.39.0 million), accounting for 125/100,000 (range 120130) globally. Most of 
the cases occurred in the WHO regions of South-East Asia, the Western Pacific 
(59%) and Africa (26%) (2). About 2.9 million cases (range 2.63.2 million), 
equivalent to 33.3% of all cases, occurred among women. The proportion of TB 
cases co-infected with HIV was estimated to be 13%, with the highest pro-
portion in the African Region, which accounts for 79% of all TB cases among 
people living with the HIV infection. Globally, the incidence rate/100,000 has 
been falling since 2001; from 2010 through 2011, it declined by 2.2%. 
In 2011, around 0.99 million deaths (range 0.841.1 million) occurred 
among HIV-negative cases of TB and an additional 0.43 million deaths (range 
0.400.46 million) among HIV-positive people, being equivalent in total to  
14 deaths/100,000 (range 1217) (2). Approximately 1.4 million people died of 
TB in 2011. A total of 0.3 million deaths occurred among HIV-negative and 
0.20 million among HIV-positive women. Globally, the mortality rates have 
fallen by more than one-third since 1990.  
From 1994, anti-TB drug-resistance data have been collected worldwide by 
the WHO and the International Union against Tuberculosis and Lung Disease 
within the Global Projects on Anti-Tuberculosis Resistance Surveillance. 
Reports have been published in 1997, 2001, 2004 and 2008; the last one in-
cludes data from 77 countries or settings (40). After that, the yearly WHO 
global TB reports include data on drug resistance. Already in 1994, drug 
resistance was reported in almost every country surveyed. Annually, 630,000 
patients (range 460,000790,000) fall ill with MDR-TB worldwide (2). In 2011, 
it was estimated that 3.7% (95% confidence interval, CI 2.15.2%) out of new 
TB cases and 20% (95% CI 1326%) of retreatment cases have MDR-TB (2). 
The probability of MDR-TB was more than 10-fold higher among previously 
treated patients (40). However, globally, only 4% of new cases and 6% of 
retreatment cases are actually tested for MDR-TB. In 2012, out of the 27 high-
MDR-TB-prevalence countries where the proportion of MDR-TB exceeded 
6.5% among never previously treated cases, 15 belonged to the WHO European 
Region. The highest reported values of MDR-TB among the new cases were in 
Belarus (32.3%), followed by those in Estonia (22.9%) (2). The WHO estimates 
that 60% out of the global MDR-TB burden lie in China, India, the Russian 
Federation, and South Africa. 
By the end of 2011, the presence of XDR-TB was reported by 84 countries. 
It was estimated that globally, approximately 9.0% (95% CI 6.711.2%) of all 
MDR-TB cases have XDR-TB, which is equivalent to 58,500 cases (4). How-
ever, the data on XDR-TB are incomplete because the low-income countries do 
not always have well equipped laboratories to perform drug susceptibility 
testing (DST) against SLDs. 
In 2011, only 4.3% of all TB cases emerged in the WHO European Region 
(2). The estimated incidence rate was 42/100,000 (range 3945), which equals 
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380,000 cases (range 350,000400,000), including 23,000 (range 20,000 
25,000) TB/HIV co-infected cases. Between 2010 and 2011, the TB incidence 
decreased by 8.5%; however, no data were available on the annual decrease of 
TB incidence in Estonia. The highest rates of difficult-to-treat M/XDR-TB are 
found in Europe. It is estimated that 15.1% (range 1020%) of all new cases 
and 44% (range 4049%) among all retreatment cases have MDR-TB, mean-
while, only 56% of new and 27% of retreatment cases were tested for MDR-TB 
in 2011. In the same year, 32,348 laboratory-confirmed MDR-TB cases were 
reported to the WHO, of which 10,290 were new and 12,097 were retreatment 
cases (2). It is estimated that 5% among the detected MDR-TB cases are XDR-
TB in the WHO European Region (41). As much as 12% of MDR-TB cases 
died in Europe in 2011. Among all TB cases the estimated mortality rate was 
5.0/100,000 (range 4.95.1). 
 
 
2.2.2. Occurrence of TB and M/XDR-TB in Estonia 
In Estonia, TB persists as a major problem, both, at the level of individual 
patients, as well as at the national level. During the 20th century the highest 
notification rate was recorded in 1953, with 417 new and relapse cases/100,000. 
By 1991, the time of the breakdown of the Soviet Union, the TB notification 
rate had decreased to the lowest level, 25.9/100,000. From 1993, as a result of 
the so-called transition shock characteristic of most of the Central and Eastern 
European countries, an increase was observed. Thus, by 1998, the notification 
rate almost doubled, being 59.4/100,000 (Figure 1). Throughout the last decade, 
the notification rate has steadily decreased below the level of that in 1991, being 
25.4/100,000 in 2011. This is also the lowest recorded TB notification rate in 
Estonia. 
From 2001, retreatment cases other than relapses are included in the case 
notification (Figure 1); however, the number of these retreatment cases is not 
large, adding only 1.7/100,000 in 2011.  
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Figure 1. Tuberculosis (TB) notification rate in Estonia, 19982011: all new cases and 
relapses, all notified cases (including all new and all retreatment cases) and all multi-
drug-resistant (MDR-TB) cases.  
 
Beginning in the 1960’s, information on drug resistance has been available in 
the laboratories in Estonia; although the first survey was carried out only in 
1994 (13) to find 10.2% of MDR-TB among new and 19.2% among previously 
treated cases. Following that, routine anti-TB drug resistance surveillance was 
established. During the last decade the notification rate of MDR-TB has been 
relatively stable, but the proportion of MDR-TB among all TB cases has 
increased, while the overall TB notification rate has decreased (Figures 1 and 
2). In 1998 the MDR-TB notification rate among all TB cases was 7.1/100,000 
and in 2011, 5.8/100,000. Among the new pulmonary TB (PTB) cases, the 
MDR-TB notification rate was 4.3 and 3.5/100,000, respectively. Meanwhile, in 
1998, the proportion of MDR-TB cases among the culture-confirmed new PTB 
cases was 13.9% and in 2011 the proportion reached the alarming level of 
23.4%. Among retreatment cases, the proportion of MDR-TB was 35.0% in 
1998 and 53.6% in 2011 (Figure 3), whereas the notification rate was 2.6 and 
2.2/100,000, respectively. Little is known about the factors possibly influencing 
the TB and M/XDR-TB epidemic in Estonia. 
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All MDR-TB 
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Figure 2. Tuberculosis (TB) notification rate in Estonia, 19982011: all new pulmonary 
TB cases; new culture- confirmed pulmonary TB cases and new pulmonary multidrug-
resistant TB (MDR-TB) cases.  
 
 
The DST to SLDs has been systematically performed since 2001. The pro-
portion of XDR-TB cases among the new pulmonary MDR-TB cases was 
10.0% (5 out of 50) in 2001 and 8.5% (4 out of 47) in 2011. Among the 
retreatment cases, the proportion of XDR-TB was significantly higher, being 
34.0% (35 out of 103) and 33.3% (10 out of 30), respectively. In 2011, the 
notification rate of all XDR-TB cases was 1.3/100,000.  
Since 2001 there has been an HIV epidemic in Estonia, resulting in a steady 
increase of notified HIV and TB co-infected cases (Figure 4). The first HIV-
positive TB case was notified in 1999, but by 2011, the number was 46 
(3.4/100,000), accounting for 12.7% of all notified cases. The proportion of 
HIV-positive cases among MDR-TB cases was 19.2% (15 out of 78), 
translating into a notification rate of 1.1/100,000, which was comparable to that 
of XDR-TB. 
In 2010, 10% of new pulmonary TB patients died during the treatment 
course in Estonia (2). However, little is known about the specific causes of 
death. 
 
Pulmonary 
Culture confirmed
MDR-TB 
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Figure 3. Tuberculosis (TB) cases in Estonia, 19982011: all multidrug-resistant TB 
(MDR-TB) cases and non-MDR-TB retreatment cases. 
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Figure 4. Tuberculosis (TB) notification rate in Estonia, 19982011: all multidrug-
resistant TB (MDR-TB) cases, all human immunodeficiency virus (HIV) cases and all 
MDR-TB and HIV co-infected cases. 
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2.3. Stop TB strategy 
To decrease global TB incidence rates and to prevent development of drug 
resistance in 1994 WHO developed the Directly Observed Short-course (DOTS) 
strategy (42) as a package of five elements, aimed at achieving at least 70% 
case detection and 85% cure rate.  
The five elements of DOTS include (43): 
1) Political commitment with increased and sustained financing;  
2) Case detection through quality-assured bacteriology;  
3) Standardised treatment with supervision and patient support;  
4) An effective drug supply and management system;  
5) Monitoring and evaluation system and impact measurement.  
 
The initial DOTS framework has subsequently been expanded to a fundamental 
pillar of the Stop TB strategy, which itself consists of six elements (44): 
1) Pursue quality DOTS expansion and enhancement;  
2) Address TB/HIV, MDR-TB and other challenges;  
3) Contribute to health system strengthening;  
4) Engage all care providers;  
5) Empower people with TB and communities;  
6) Enable and promote research.  
 
In 2011, 182 WHO Member States out of a total of 194 reported on the progress 
achieved in TB control (2). The Stop TB targets set for 2012 and 2050 are to 
reduce prevalence and death rates by 50% compared to their levels in 1990 and 
to reduce the global incidence rate of active TB cases to less than 1 case per 
million population per year. However, globally not all countries and regions 
will achieve the WHO-set targets; therefore, one of the aims of our study was to 
assess the barriers to reaching the targets globally and specifically in the WHO 
European Region, which includes Estonia. 
In 2000, the WHO and the Stop TB Partnership launched an initiative, the 
Green Light Committee (GLC), to support countries to manage MDR-TB and to 
prevent development of further drug resistance. The GLC’s role was to review 
applications from countries and projects wishing to purchase concessionally-
priced SLDs and determine whether such projects would be in line with the 
WHO guidelines (45). Such projects were eligible for technical assistance 
provided by members of the GLC.  
In 1998, the Estonian NTP adopted the DOTS strategy with all five com-
ponents and reached a countrywide expansion by 2000. The first five-year TB 
programme for the period 19972003 aimed at decreasing TB incidence among 
new cases to 30/100,000 population by 2005. The current, third five-year TB 
programme aims at decreasing TB incidence among new cases to 20/100,000. 
In 2001, due to the alarmingly high rate of MDR-TB and the lack of SLDs to 
treat these patients, the NTP applied to the GLC for the countrywide project on 
management of MDR-TB, which started on the 1st of August 2001. The 
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technical support has been provided to the NTP by WHO and The International 
Union against Tuberculosis and Lung Diseases. Furthermore, technical and 
financial support has been provided by the Finnish Lung Health Association, 
the joint project of the Non-Governmental Organizations in the Nordic 
Countries, the Centers for Disease Control and Prevention, Atlanta, USA, and 
the Open Estonia Foundation. From 2001 onward all TB-related services in 
Estonia have been funded from domestic sources (2). 
Currently, the effect of the countrywide availability of the SLDs on 
incidence of TB, as well as MDR-TB, has not been evaluated either globally or 
in Estonia. Therefore, one of the aims of our study was to evaluate the impact of 
the countrywide availability of SLDs on the TB and MDR-TB incidence. 
 
 
2.4. Incidence of TB and M/XDR-TB  
TB incidence depends on the presence of the source of infection and trans-
mission of the infection in the society (1). To interrupt the chain of transmission 
the source should be eliminated (diagnosed and treated) as soon as possible. 
There are numerous challenges on the way to the elimination of TB and 
M/XDR-TB. The risk factors for being exposed to infection, for developing the 
disease after being infected and for mortality, are largely overlapping. This 
section presents a short overview of the known risk factors.  
 
 
2.4.1. Risk of developing TB and M/XDR-TB disease 
Following an infection with M. tuberculosis the host organism has approxi-
mately 10% lifetime risk of developing TB disease, with half of the risk falling 
within the first 5 years following the infection (1). The risk of TB among HIV-
positive persons is much higher, up to 510% annually (1), as the HIV infection 
impairs cell-mediated immunity. Among 2,737 newly HIV-seroconverted South 
African gold miners, the incidence of TB doubled within the first year of HIV 
infection (adjusted risk ratio, ARR 2.1; 95% CI 1.4–3.1) (46). 
HIV infection not only aids the progression of a TB infection into disease, 
but also increases the severity of the TB disease by undermining granuloma 
formation, mainly due to impairing the maturation of macrophages in the lungs 
(47, 48). On the other hand, TB exacerbates the acquired immunodeficiency 
syndrome (AIDS) by increasing viral replication, where the possible mecha-
nisms include: 1) stimulation of HIV-1 production by inflammatory cytokines, 
mainly by tumour necrosis factor-, 2) increasing the expression of chemokine 
receptors CXRC-4 and CCR5 and 3) down-regulating the chemokine receptor 
CCL5 (4749). 
In addition to HIV infection, there are multiple other interacting factors 
influencing the development of TB disease (1, 50, 51): 
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1) The factors that depend on the host organism like age, sex, ethnicity, body 
build, and pregnancy;  
2) Medical factors: immunosuppressive treatment, renal failure, haemophilia, 
gastrectomy and jejunoileal bypass, carcinoma, pneumoconiosis (silicosis, 
coal worker’s pneumoconiosis), and diabetes; 
3) Genetic factors: human immune response to TB;  
4) Environmental factors: poverty, occupation, diet, smoking, alcohol and drug 
abuse, place of residence (urban vs. rural), etc.;  
5) Factors associated with M. tuberculosis: infecting dose and strain virulence. 
 
As for the risk factors for developing M/XDR-TB, a review of 29 papers by 
Faustini et al. (52) concluded that the pooled risk of MDR-TB was 10.23 times 
higher in previously treated than in never treated cases. The risk estimates were 
higher in studies carried out in Western Europe (risk ratio, RR 12.63; 95% CI 
8.2019.45) than in Eastern Europe (RR 8.53; 95% CI 6.5711.06). The 
patients with MDR-TB were more likely to be foreign born (odds ratio, OR 
2.46; 95% CI 1.863.24), younger than 65 years (OR 2.53; 95% CI 1.744.83), 
male (OR 1.38; 95% CI 1.161.65), and HIV positive (OR 3.52; 95% CI 
2.485.01). In Estonia, the risk factors for developing MDR-TB were: previous 
anti-TB treatment (OR 4.11; 95% CI 2.776.08), being younger than 65 years 
of age 24 years or younger (OR 2.57; 95% CI 1.096.06), 2544 years (OR 
2.64; 95% CI 1.355.16), and 4564 years (OR 2.06; 95% CI 1.063.99), 
female sex (OR 6.23; 95% CI 1.0237.99) and birth outside of Estonia (OR 
82.04; 95% CI 3.461945.47) (53). The determinants of XDR-TB were: 
previous anti-TB treatment (OR 10.54; 95% CI, 5.9718.62), HIV infection 
(OR 3.12; 95% CI, 1.317.41), homelessness (OR 2.73; 95% CI 1.156.48), 
and alcohol abuse (OR 1.98; 95% CI 1.083.64) (53). 
Once the infectious TB and M/XDR-TB individuals are present in the 
community and disseminate infection, these factors play a significant role in 
increasing the number of patients with both active TB and M/XDR-TB disease. 
Beyond addressing the socio-economic and clinical factors to decrease the risk 
of contracting infection and developing the disease, it is of pivotal importance 
to diagnose infectious cases early and provide prompt effective treatment to halt 
the infectiousness. The impact of the various risk factors listed above on TB and 
MDR-TB notification in Estonia is not known; therefore one of our studies was 
designed to evaluate the impact of poverty and HIV on TB and MDR-TB 
notification rates. 
 
 
2.4.2. Treatment and recurrence of TB and M/XDR-TB 
Besides the immediate treatment success, the effectiveness of the treatment is 
measured by the rate of TB recurrence after successful treatment. In cases of 
non-HIV-infected drug-sensitive TB patients with RMP included in the 
treatment regimen at least in the intensive phase, it is possible to achieve 
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9799% treatment success with an average disease recurrence rate of less than 
5% (6). 
It has been proven that FLDs are not effective in the treatment of MDR-TB. 
Studies addressing the treatment success among MDR-TB patients using FLDs 
have found that the treatment success rate was low and the relapse rate was 
high. In a study from China, MDR-TB patients treated with FLDs had a treat-
ment success of 6683%, while 57% of patients had disease recurrence during  
4 years of follow-up (54). In an 18-month follow-up study of patients treated 
with FLDs in four districts in Karakalpakstan, Uzbekistan, 6% and 43% 
mortality and 23.0% and 60.0% disease recurrence were found for TB and 
MDR-TB, respectively (55). 
Management of patients with drug-resistant TB, i.e. mono-resistant, 
polydrug-resistant (PDR-TB), and particularly M/XDR-TB, is complicated 
because of the longer treatment, lesser effectiveness of anti-TB drugs and more 
side effects. Mono-resistance refers to resistance to a single anti-TB drug and 
PDR-TB refers to resistance to two or more anti-TB drugs but not to both INH 
and RMP. The patients with M/XDR-TB remain infectious for longer periods as 
the sputum conversion is slower, the overall treatment success lower and 
mortality significantly higher than among those with non-MDR-TB (5659). 
Furthermore, because of the high cost of the SLDs, the management of 
M/XDR-TB represents a significant monetary burden for TB programmes (60). 
The treatment of MDR-TB cases using internationally recommended treat-
ment regimens with SLDs provides better results. Although noted among 
patients specially selected for the GLC-project, the treatment success was up to 
77% among new and up to 69% among previously treated cases (61). In a meta-
analysis by Johnston et al. (62), the pooled treatment success of 27 studies was 
much lower, 62% (95% CI 57–67), while 11% (95% CI 9–13) of patients died.  
In India, MDR-TB patients enrolled on a standardized MDR-TB treatment 
regimen, i.e. a regimen of same drugs for all patients in a given area, reported a 
treatment success of 61% (63). In South Korea, the treatment success among 
MDR-TB patients treated with individualized treatment regimens, i.e. drug 
regimens tailored according to the DST results, was higher, reaching 73.2% 
(10). Orenstein et al. (64) compared data on treatment success of individualized 
vs. standardized treatment regimens from 29 studies. The patients with MDR-
TB treated with individualized regimens had a treatment success of 64% (95% 
CI 59–68%) vs. 54% (95% CI 43–68%), when using standardised regimens, 
although this difference was not statistically significant. The proportion of those 
who died during the treatment was 11% and 12%, respectively; again, the 
difference was not statistically significant.  
The treatment success among TB patients is known to be decreasing in the 
following order: drug-sensitive TB  PDR-TB  MDR-TB  XDR-TB. Thus, in 
Abkhazia, Georgia, the treatment success of patients with different resistance 
patterns was compared and it was found that 85.2% of patients with drug-
sensitive TB completed the treatment successfully, while those with PDR-TB 
had a treatment success of 78.3% and those with MDR-TB only 32.3% (65). 
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Pulmonary MDR-TB and XDR-TB patients treated with individualized 
treatment regimens in Estonia during the period 20032005 had a treatment 
success of 60.4% and 42.6%, respectively (66). The difference was statistically 
significant. During the period from 2002 to 2004, a total of 1,027 M/XDR-TB 
patients were enrolled on individualized treatment regimens in Latvia. The 
treatment success was 67.9%, with a statistically significant difference between 
MDR-TB and XDR-TB patients (69.3% and 38%, respectively) (67). In Tomsk, 
Russia, the difference between the treatment success of MDR-TB (66.7%) and 
XDR-TB (48.3%) patients was also statistically significant (68). However, the 
difference between the treatment success of XDR- and MDR-TB patients is not 
always significant, as for example in Peru, where 66.3% of MDR-TB patients 
and 60.4% of XDR-TB patients were successfully treated (69). In a study 
assessing treatment results among XDR-TB patients pooled together from  
4 countries/settings, the treatment success was as low as 39.3% (70). The lowest 
reported treatment success among non-HIV-infected XDR-TB patients was in 
South Korea, or only 18% (71).  
It was mentioned before that the effectiveness of treatment is measured by a 
stable cure and the aim is to have not more than 5% TB recurrence (6). It has 
been shown that it is possible to achieve as low as 5% recurrence in case of 
drug-sensitive TB, but the follow-up time of the majority of studies did not 
exceed 3 years. According to the 2008 systematic review of 16 studies by Cox 
et al. (8), the disease recurrence rates after successful treatment ranged from 
014%. The median follow-up time in these studies ranged from 12 to  
31 months. Chang et al. (72) found that out of 12,183 patients with mainly non-
resistant pulmonary TB in Hong Kong, 0.9% (95% CI 0.8–1.1%) relapsed 
within 30 months after commencement of therapy. A study from Spain reported 
4.3% TB recurrence among successfully treated predominantly drug-sensitive 
TB patients after as long as 8-year follow-up (73). 
The patients with recurrent disease are known to be at higher risk for 
M/XDR-TB and mortality, as found by Jeon et al. (71) and, also in a review by 
Johnston et al. (62). Little is known about the rate and time of recurrence among 
drug-resistant TB cases. Moreover, none of the studies is of a country wide 
design. In South Korea, the pooled treatment success of drug resistant cases was 
45.3%, or 46.2% among MDR-TB and 29.3% among XDR-TB cases. In that 
study the total disease recurrence during 37 years of follow-up from the 
beginning of treatment was 8.9%, or 13.6% among XDR-TB and 8.8% among 
MDR-TB cases (74). In a previously mentioned study from South Korea, the 
disease recurrence of MDR-TB patients treated with individualized treatment 
regimens was 4.4% during the median follow-up period of 38.7 months (10). 
The recurrence of TB after treatment of pulmonary MDR-TB in Peru with a 
minimum follow-up time of 24 months after treatment was 5.1% (95% CI 
3.08.2) (75). None of the studies referred to were of countrywide design. In 
2001, country wide management of M/XDR-TB was launched in Estonia, but 
until now no data have been available to determine the long-term effectiveness 
of the treatment regimens used at that time.  
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Numerous studies have demonstrated an association between HIV status and 
TB death. In Brazil, a total of 161,481 drug-sensitive TB patients were 
evaluated for treatment success, which was 85.7% among HIV-negative and 
55.7% among HIV-positive persons, while the mortality was 4.2% vs. 23%, 
respectively (76). When stratifying mortality by HIV infection in 22 relevant 
studies, Straetemans et al. (77) found that mortality was significantly higher 
among HIV-infected drug-sensitive persons compared to non-HIV-infected 
(9.2% vs. 3.0%). In the Netherlands, Borgdorff et al. (78) found that the HIV-
infected TB patients had an increased risk of death compared to non-infected 
patients (hazard ratio, HR 9.9, 95% CI 5.418). In a study by Mallory et al. (9) 
from South Africa, HIV infection was associated with a significantly higher TB 
recurrence compared to non-HIV-infected patients (8.2 vs. 2.2 per 100 person-
years; multivariate-adjusted incidence RR 4.9, 95% CI 3.0–8.1). Furthermore, 
HIV-positive patients continue to die more rapidly after completion of anti-TB 
treatment. In Zomba, Malawi, up to seven years after completing the TB 
treatment, the HIV-infected patients had higher death rates than the HIV-
negative ones (HR 2.2, 95% CI 1.72.8) (79). In sub-Saharan Africa, 25.7% of 
deaths among the HIV-positive patients occurred during anti-TB therapy, while 
the rest of the deaths (74.3%) occurred during the 2.5-year period after suc-
cessful completion of anti-TB therapy (80). It is known that the cause of death 
among the HIV-positive patients after completing TB treatment is most often 
not TB but rather AIDS-related causes, including Mycobacterium avium 
complex infection, Pneumocystis jiroveci pneumonia, non-Hodgkin’s lympho-
ma, etc. (81, 82). This evidence makes it important to ensure early initiation of 
highly active antiretroviral therapy (HAART) in HIV-infected patients with TB 
(80, 83, 84). 
The death toll is known to be much higher in cases of M/XDR-TB and HIV 
co-infection. In a cohort of South African MDR-TB patients, 35.2% of HIV-
positive died versus 1.62% HIV-negative ones (P0.0001) (85). The particularly 
deadly liaison of M/XDR-TB and HIV has been demonstrated in a study from 
KwaZulu Natal, South Africa, where 52 of 53 (98.1%) patients with XDR-
TB/HIV co-infection died within 16 days from the time of diagnosis (7). In 
another study from KwaZulu Natal, HIV co-infection was an independent risk 
factor for death (adjusted odds ratio, aOR 5.6) among 1,209 MDR-TB patients 
(86). In Lima, Peru, 57% of HIV-positive individuals (31 out of 52) died on 
treatment, with a majority of deaths occurring due to MDR-TB (83). However, 
in that study, individuals receiving HAART showed a lower mortality compared 
to those without such treatment (HR 0.4 95% CI 0.20.9). In Thailand the 
survival of MDR-TB patients was reduced in case they were co-infected with 
HIV (HR 11.7; 95% CI 2.1–64.9). In the same study, the absence of HAART 
was an independent risk factor for death (HR 7.9; 95% CI 1.5–43.1) (87). 
HAART has been shown to significantly improve not only the survival, but 
even the overall treatment outcome of HIV-infected XDR-TB patients (88). To 
conclude, there is an international consensus that an effort should be made to 
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prevent TB in people with HIV infection and to provide comprehensive HIV 
care in association with directly observed therapy for TB/HIV (89, 90). 
Apart from HIV infection, other risk factors for poor treatment outcome and 
mortality have been thoroughly studied. Nevertheless, these studies are mainly 
done either on drug-sensitive TB or with inclusion of all TB cases. Fortunately, 
during the last decade, there have been several studies available also on MDR-
TB. The risk factors for poor treatment outcome and mortality are largely 
similar to those for TB infection and progression to disease and include: 1) 
demographic factors: male sex (62, 9193), older age (78, 80, 91, 94100), 
younger age in a low-income country (92); 2) socio-economic and life-style 
factors: low BMI and hypoalbuminemia (51, 62, 74, 80, 83, 100102), poverty 
or social marginalization (51, 100, 102), marital status (102) educational level 
(51, 100, 102), imprisonment (institutionalization) in the past (100, 102), 
smoking and air pollution, although it is considered to be more evidence of the 
relationship between TB disease than association between TB infection and 
mortality (11, 51, 77, 92, 100, 102110), alcohol abuse (51, 62, 66, 92, 98, 100, 
102, 111, 112), overall co-morbidities (93, 100, 101, 113), HIV infection (7, 11, 
62, 64, 83, 100, 114); and 3) TB-related factors: previous anti-TB treatment (62, 
66, 71, 74, 98, 115), extent of disease and/or cavitary disease (71, 92, 97, 112, 
113), smear positivity at diagnosis (62, 66, 92, 100, 115), smear negative at 
diagnosis in HIV-infected patients (100), different composition of treatment 
regimens (64, 116). 
 
 
2.5. TB and M/XDR-TB mortality 
Mortality from TB is an important indicator for monitoring the effectiveness of 
treatment regimens, but also of the capacity of TB control programmes to 
diagnose TB and manage the patients. The M/XDR-TB has been associated 
with high mortality rates during treatment (717%) (62, 64, 70), particularly 
among HIV-infected patients (7, 83), as previously mentioned. 
According to the WHO recommendations for TB programmes, the definition 
for treatment outcomes include definition of death, i.e. a patient who dies from 
any cause during the course of treatment (117). This definition, however, 
excludes deaths that occur among TB patients after treatment failure, default 
from treatment and transfers out, and therefore underestimates the true mortality 
among TB patients. Furthermore, this definition includes all other causes of 
death apart from death due to TB itself. In a study by Straetemans et al. (77), the 
pooled percentage of TB patients dying of TB itself during treatment among 
HIV-infected persons was 9.2% (95% CI 3.7–14.7%) and among HIV-un-
infected persons, 3.0% (95% CI 21.2–7.4%), whereas the pooled percentage of 
TB patients dying due to any cause during TB treatment was 18.8% (95% CI 
14.8–22.8%) and 3.5% (95% CI 2.0–4.92%), among HIV-infected and HIV-
uninfected persons, respectively.  
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To improve the evaluation of the NTP efficiency, it has been proposed to 
estimate mortality among TB patients recorded in vital registration (VR) 
systems along with the internationally-recommended standard treatment 
outcome definitions for TB (118). However, Korenromp et al. (119) has urged 
using the standard definitions of the causes of deaths in both national VR 
systems as well as in the cohort treatment outcome reports in a way that would 
allow both systems to adhere to the International Classification of Diseases and 
Related Health Problems (ICD-10). 
In cases when the VR system is not in place alternative methods should be 
used. In the sample registration system, events are recorded routinely from a 
representative sample of the population and demographic surveillance systems 
using verbal autopsies to assess causes of death (120). However, the reliability 
of the method of verbal autopsy has been increasingly questioned, as it includes 
inherent errors, mainly due to the expert errors in determining the cause of death 
(121, 122). Thus, the cause of death may be recorded differently, depending 
largely on the subjectivity and training of the experts. For example, a 
publication from Taiwan by Lu et al. (123) points out that the doctors trained in 
diverse local and foreign educational systems use different terminology in the 
native language for the same diagnosis. Sibai (120) in his paper concludes, 
based on the one by Lenfant et al. (124), that the reporting of causes of death is 
less accurate, when the death is sudden, attributable to a stigmatized condition, 
or occurs among certain minorities, social classes and older age groups. In the 
case of TB, at least three out of these occasions certainly apply. 
In 2003 the VR systems of 115 countries, including Estonia, were assessed 
for timeliness, completeness and coverage of registration and the proportion of 
deaths assigned to ill-defined causes. The VR system in Estonia was evaluated 
as being of high-quality with 100% completeness and coverage and only 5% of 
deaths being coded as ill-defined (125). However, there is also some possible 
misclassification in the Estonian VR system, as identified in the classification of 
alcohol poisoning in the mortality statistics (126). In 2011, WHO used for the 
first time the VR data from 91 countries representing 46% of the deaths caused 
by TB to estimate the global TB-mortality (90). Those countries had well-
functioning VR systems defined as the following: 1) coverage of at least 70% of 
the population, and 2) ill-defined causes of death (ICD-19 code B46, ICD-10 
codes R00R99) of less than 20% of all registered death (125). In cases when 
the VR was for some reason incomplete, sample VR systems or mortality 
surveys were used to obtain direct measurements of TB deaths. Before 2011, the 
estimates of TB mortality were based on the data from 89 countries, mainly 
from the European region and regions in the Americas, representing only 8% of 
the world’s TB cases. The improved quality of the data on TB mortality allowed 
revising the global estimates. Thus in 2010, in total, 1.4 million (range 1.2 
1.5 million), including an estimated 0.35 million deaths (range 0.320.39 mil-
lion) among HIV-positive cases occurred due to TB. The WHO estimate 
published in 2011 was lower than that published in 2010 (1.7 million, including 
0.4 million among HIV-positive people) (127). 
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It is well established that patients with TB have an increased risk of death 
during and after treatment as compared to the general population. While there 
are several studies on the standardized mortality ratio (SMR) and causes of 
deaths during and after TB treatment, there are neither studies addressing 
specifically M/XDR-TB patients nor studies from countries with a high MDR-
TB incidence, like Estonia. A study of fatality in patients with pulmonary TB, 
diagnosed in England and Wales in 1983 (97) and followed up until the end of 
anti-TB chemotherapy, found, using standardized rates, that the all cause 
mortality among people with PTB was 10 times higher than that of the general 
population. The case fatality in that study was 12.9%. A retrospective survey of 
TB patients in Liverpool (99) with an 8-year follow-up period revealed that 
patients previously diagnosed with TB were 4.5 times more likely to die (95% 
CI 3.7–5.4) than did the general Liverpool population. Furthermore, subjects 
below 75 years of age had a high mortality from cancer. There are two studies 
from India with an average follow-up time of 1.6 (92) and 3.3 years (128), 
respectively. The case fatality was 9.4% in the first and 20.4% in the second 
study, the all cause mortality compared to the general population was 6.1 (95% 
CI 5.46.9) and 4.2 (95% CI 3.94.5) in the urban and sub-rural cohort, 
respectively. Furthermore, the mortality of TB patients continues to be higher 
than in the general population even after successful treatment. A 4.5-fold (95% 
CI 3.42–5.57) excess all cause mortality rate was found among successfully 
treated drug-sensitive TB patients in a study from southern Ethiopia with an 
average follow-up time of 3.6 years (91). 
Up to now, the causes of the death of TB and MDR-TB patients and their 
assumed excess mortality compared to the general population has not been 
evaluated in Estonia, even though this information is important in order to 
improve the survival of this group of patients, particularly considering that in 
Estonia, the majority of TB and MDR-TB patients are of working age.  
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3. AIMS OF THE STUDY 
The overall aim was to evaluate the impact of M/XDR-TB on the TB notifica-
tion rate, disease recurrence and mortality, and to identify the causes of death of 
TB and M/XDR-TB patients.  
 
The specific aims of the studies were:  
 
Paper I To identify the global barriers to reaching the targets for TB 
control. 
 
Paper II To evaluate the impact of countrywide management of TB and the 
availability of SLDs on the notification rates of overall pulmonary 
TB and MDR-TB, taking into account HIV co-infection and the 
national economy in Estonia. 
 
Paper III To assess the treatment outcome of the first GLC-approved 
countrywide management of MDR-TB and XDR-TB in Estonia 
and to evaluate risk factors contributing to TB recurrence.  
 
Paper IV To assess overall and cause-specific mortality among TB and 
MDR-TB patients at the diagnosis and after successful completion 
of treatment compared to the general population in Estonia. 
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4. METHODS 
This section encompasses the study population, definitions, laboratory methods, 
treatment regimens and modalities of TB and M/XDR-TB management, data 
collection and statistical methods. 
 
 
4.1. Study population 
This thesis is based on one round table article and the results of three studies 
which were carried out on partly overlapping cohorts consisting of subjects 
diagnosed with TB or M/XDR-TB in Estonia during the period January 01, 
1998 to December 31, 2009. The partly overlapping cohorts and the different 
time periods of the studies were determined by the specific aims and timing of 
the studies. Throughout all the studies the subjects who emigrated were defined 
as transferred out from Estonia and were excluded from analysis. The Ethics 
Committee on Human Research at the University of Tartu, Estonia, approved 
the study protocols. 
 
Paper I 
The round table article identifying the main barriers to reaching the targets for 
TB control in the different regions of the world covered data available from 
various publications, including the WHO reports on TB, MDR-TB and HIV/ 
AIDS. The population covered by WHO annual reports on TB has been steadily 
increasing. Thus, only 65 countries or 29% of WHO Member States submitted 
their data directly to the WHO for the 1993 report (129), while the 2006-WHO 
report (130), which was the latest assessed document for the Paper, covered 200 
out of 211 countries and territories. The reports on drug-resistance included 
publications on various populations starting from 1943 as well as the WHO 
reports on anti-TB drug resistance surveillance. The first WHO report on drug 
resistance (13) summarizes data made available from 35 countries, whereas in 
the 2004 report (131) data on drug resistance were available from 77 countries 
or settings (70% of 194 Member States). The Paper included data on noti-
fication of TB and MDR-TB in Estonia during the periods January 1, 2000 
through December 31, 2000 (131) and the treatment outcome of MDR-TB 
patients notified in Estonia from August 1, 2001 through December 31, 2001 
(61). 
 
Paper II 
All subjects from both the civilian and the penitentiary sectors who fulfilled the 
criteria for PTB diagnosed during the period 1998–2006 were included to 
evaluate the impact of countrywide management of TB and M/XDR-TB 
patients on the respective notification rates in Estonia. Patients with extra-
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pulmonary TB and retreatment cases other than relapses were excluded from the 
analyses. 
The beginning of the study was determined by: 1) the start of imple-
mentation of the DOTS strategy in Estonia in 1998 and 2) launching the country 
wide management of M/XDR-TB in 2002. The two observation periods 
(January 01, 1998 through December 31, 2001 and January 01, 2002 through 
December 31, 2006) were defined to evaluate the effect of the country wide 
availability of SLDs on TB and M/XDR-TB notification rates. 
 
 
Paper III 
In Paper III the treatment outcome of M/XDR-TB patients as well as recurrence 
of TB among those successfully treated was evaluated. All subjects diagnosed 
with active pulmonary or extra-pulmonary M/XDR-TB from both civilian and 
penitentiary sectors in Estonia during the period August 01, 2001, through July 
31, 2003, were included with the exclusion of those who received treatment 
with SLDs for less than 1 month. The subjects enrolled were followed until 
December 31, 2010. 
 
Paper IV 
The excess mortality and causes of death of all patients diagnosed while alive 
with new respiratory TB during the period from January 01, 2002 through 
December 31, 2009 were measured. The subjects included belonged to the age 
group of 25–64 years and were followed up until death, emigration or until 
December 31, 2011, whichever event occurred first. Two cohorts were defined: 
one involved everyone fulfilling the criteria for inclusion and the second was 
composed only of the successfully treated patients from the former group. The 
subjects with an unknown survival status at the end of the observation period 
were excluded (Figure 5). The beginning of the study period (January 01, 2002) 
coincided with the country wide availability of FLDs and SLDs. 
 
 
4.2. Definitions 
WHO TB and M/XDR-TB case definitions, as well as treatment outcome 
definitions, were used (132-134). The TB cases were classified as pulmonary or 
extra-pulmonary. The case definitions used in the studies were as follows: 
 New case – a patient who has received no anti-TB treatment or has received 
it for less than one month. 
 Relapse – a patient whose most recent treatment outcome was “cured” or 
“treatment completed” and who is subsequently diagnosed with bacterio-
logically positive TB by sputum smear microscopy or culture. 
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 Retreatment cases other than relapses included treatment after default, 
treatment after failure, and others. Others were patients who did not fit into 
any of the above categories.  
 Chronic case  a patient who remained smear-, sputum- or culture-positive 
after completing a retreatment regimen.  
 
The definitions used for recording treatment outcome were: 
 Cured: 1) In case of drug-sensitive TB – a patent whose sputum smear or 
culture was positive at the beginning of the treatment but who was smear- 
or culture-negative during the last months of treatment and on at least one 
previous occasion; 2) in case of M/XDR-TB – a patient who has completed 
treatment and has at least five consecutive negative cultures from samples 
collected at least 30 days apart during the final 12 months of treatment.  
 Treatment completed – a patient who has completed treatment but does not 
meet the definition for cure because of a lack of bacteriological results. 
 Failed: 1) in case of drug-sensitive TB, the treatment is considered to have 
failed if sputum smear or culture is positive at 5 months or later during 
treatment, and 2) in case of M/XDR-TB, the treatment is considered to have 
failed if two or more of the five cultures recorded in the final 12 months of 
therapy are positive or if any of the final three cultures is positive.  
 Defaulted – a patient whose treatment was interrupted for two or more 
consecutive months. 
 Died – a patient who dies for any reason during the course of treatment. 
 Successfully treated patients were defined as the sum of patients who were 
cured and those who completed the treatment. A poor treatment outcome 
was defined as the sum of treatment failures, defaulters of treatment, and 
those who died.  
 Patient with respiratory TB (IV)  a patient who has TB of respiratory 
organs, confirmed or not by bacteriological or histological means (ICD-10 
A15A16). 
 Bacteriological confirmation of subjects by culture was used instead of that 
by smear; M/XDR-TB, as well as non-M/XDR-TB was confirmed by DST. 
Non-M/XDR-TB cases included those with drug-sensitive TB or any 
pattern of resistance other than M/XDR-TB. The disease recurrence was 
confirmed by culture without performing genotyping of isolates to diffe-
rentiate between recurrence caused by the former strain and re-infection. 
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4.3. Laboratory methods 
According to the country policy, at the diagnosis, three smear microscopies had 
to be performed and at least two samples of a biological material from affected 
sites were sent for culture and DST to FLDs. In cases when mono-drug-resis-
tance, PDR-TB, or MDR-TB was confirmed, DST to SLDs was done routinely.  
From 1997, the TB laboratory network in Estonia has been quality-assured 
by the supranational reference laboratory, the Swedish Institute for Infectious 
Disease Control (SMI). From 1998 onwards, culture and DST were routinely 
performed and recorded. The cultures were performed on conventional 
Löwenstein-Jensen solid media and in BACTEC® broth media using BACTEC® 
MIGIT960 fluorometric mycobacterial detection system or BACTEC® 
MIGIT460 radiometric system (both from Becton Dickinson Diagnostic 
Systems, Sparks, MD, USA). For identification of species, the AccuProbe TM 
Rapid DNA Probe Test (Gen-Probe Inc., San Diego, CA, USA) and GenoType® 
MTBC (Hain LifeScience GmbH, Nehren, Germany) were used. DST was per-
formed by the proportion method using BACTEC® MIGIT460 (Becton Dickin-
son) for nine drugs: INH (0.2 µg/mL), RMP (2.0 µg/mL), STM (4.0 µg/mL), 
ethambutol (EMB) (5.0 µg/mL), AMK (2.0 µg/mL), KM (5.0 µg/mL), CPM 
(5.0 µg/mL), prothionamide (PTH) (5.0 µg/mL) or ethionamide (ETH)  
(5.0 µg/mL) and ofloxacin (OFX) (2.0 µg/mL). From 2003, the DST for 
pyrazinamide (Z) (100.0 µg/mL) was performed. Resistance was defined as the 
presence of growth of >1% of the colonies in the drug-containing media, 
compared with the growth in the drug-free medium.  
Smears were stained with Ziehl-Neelsen method and/or fluorochrome. 
Competence in performing sputum smear microscopy, culture and DST for 
INH, RMP, STM and EMB was ensured by quality assurance procedures 
organised by the Estonian Reference Laboratory of Tuberculosis and Myco-
bacterioses (ERLTM) and by the SMI. Random verification of DST results for 
KM, CPM, ETH, AMK and OFX was performed by the SMI.  
 
 
4.4. Treatment 
For the treatment of drug-sensitive and bacteriologically non-confirmed TB 
cases the internationally recommended standardized short-course treatment 
regimens, such as category I for new cases and category II for previously treated 
cases, were used. Commonly, the category I treatment regimen consisted of 
daily dosing of INH, RMP, EMB and Z for 2 months, followed by INH and 
RMP once daily three times per week for 4 months. Category II treatment 
regimen consisted of daily dosing of INH, RMP, EMB, Z and STM, followed 
by one month of INH, RMP, EMB and Z and 5 months of INH and RMP once 
daily three times per week. 
For treatment of mono-resistant or PDR-TB, the treatment regimens re-
commended by the Partners in Health (135) were used (Table 1). In case of 
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M/XDR-TB individualised treatment regimens were designed based on the 
GLC-approval in 2001: 
 The treatment regimen consisted of at least four oral drugs (a fluoroquino-
lone, PTH, CS, Z) and one of the second-line injectables, KM, CPM or 
AMK; SM could be used if the strain was confirmed to be susceptible; 
 EMB was added if the strain was susceptible; 
 Para-aminosalicylic acid (PAS) was added in case of extensive resistance or 
intolerance of other drugs; 
 Agents with an unclear role in M/XDR-TB treatment, such as amoxicillin/ 
clavulanate and clarithromycin, were added in case of poly-resistance to 
SLDs; 
 Injectables, STM, KM, AMK and CPM, were used until 23 consecutive 
months of culture-negative results had been obtained, but not for less than 6 
months; 
 The total duration of treatment was at least 18 months after bacteriological 
conversion.  
 
Table 1. Commonly used treatment regimens in case of polydrug-resistant tuberculosis 
(PDR-TB) in Estonia, 20022011 
 
Patterns of drug resistance Suggested regimen 
 Intensive phase 1  Continuation phase 1 
INH (± STM) 3 RMP, Z and EMB (± STM) 6 RMP, Z and EMB  
 
INH and Z 6 STM, RMP, EMB and a 
fluoroquinolone 
 
6 RMP, EMB and a 
fluoroquinolone  
 
INH and EMB 6 STM, RMP, Z and a 
fluoroquinolone  
 
6 RMP, Z and a fluoroquinolone 
 
RMP 6 INH, EMB, Z , STM and a 
fluoroquinolone  
 
6 INH, EMB, Z and a fluoro-
quinolone 
 
RMP and EMB (± STM) 
 
6 KM, INH, Z, PTH2 and a 
fluoroquinolone  
 
12 KM, INH, Z, PTH2 and a 
fluoroquinolone 
 
RMP and Z (± STM) 
 
6 KM, INH, EMB, PTH2 and 
a fluoroquinolone  
 
12 KM, INH, EMB, PTH2 and a 
fluoroquinolone 
 
INH, EMB and Z (± STM) 6 KM, RMP, PTH2, CS and a 
fluoroquinolone 
 
12 KM, RMP, PTH2, CS and a 
fluoroquinolone 
 
1 The number indicates the duration of the respective treatment phase with the drugs pro-
vided in months. 2 Prothionamide (PTH) and ethionamide (ETH) were interchangeable. 
AMK: amikacin; CPM: capreomycin; CS: cycloserine; EMB: ethambutol; INH: iso-
niazid; KM: kanamycin; PAS: para-aminosalicylic acid; RMP: rifampicin; STM: 
streptomycin; Z: pyrazinamide. 
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The treatment regimens were slightly different from the 2011-WHO M/XDR-
TB guidelines (84), where longer use of an injectable agent (minimum  
8 months) and use of a newer generation of fluoroquinolone, such as levo-
floxacin and moxifloxacin instead of ofloxacin was recommended. From 2006, 
levofloxacin as the preferred fluoroquinolone agent replaced ofloxacin in the 
treatment regimens in Estonia. 
The treatment of non-MDR-TB patients was carried out under direct ob-
servation six times per week during the intensive phase (i.e. first 23 months of 
treatment) and three times per week during the continuation phase. Treatment of 
M/XDR-TB patients was directly observed six times per week during the whole 
treatment course. However, in cases where the SLDs were administered twice 
per day, then only the first daily dose was given under direct supervision. All 
patients were receiving social support in the form of food parcels and trans-
portation support to and from the health care centre, which equalled to an 
average USD 2.5 per day. 
 
 
4.5. Data collection 
To create the study-specific databases, the TB-related data for the three studies 
(IIIV) were extracted from the Estonian Tuberculosis Registry (ETR) data-
base. The ETR database is continuously updated from standardized NTP forms 
completed by the physicians and nurses involved in management of TB 
patients. The study data were reviewed by the principal investigator with an 
assistance of the ETR personnel and physicians responsible for patient 
management to verify the results and to complete the missing data. The data on 
drug resistance and smear and culture results were obtained from the ERLTM. 
For calculation of the incidence and mortality rates, the mid-year population 
was downloaded from the Statistical Office of Estonia (136). The data on HIV 
infection in Estonia originated from the Health Board (137). Follow-up for 
death or emigration was carried out at the Estonian Mortality and Population 
Registries by using a unique personal identification number and/or name date of 
birth, and place of residence. The causes of death, which to our prior judgment, 
could be affected by residual TB sequelae, anti-TB treatment or known 
behavioural risk factors for TB disease (50), such as smoking and alcohol abuse, 
were chosen in order to analyse the mortality of TB and M/XDR-TB patients 
(IV). Due to the possible misclassification of alcohol poisoning in the mortality 
statistics, which is recognized in Estonia (126), the selected alcohol-related 
causes of deaths like mental and behavioural disorders due to alcohol abuse 
(F10 according to the ICD-10), alcoholic cardiomyopathy (I42.6), alcoholic 
liver disease (K70) and accidental poisoning by and exposure to alcohol (X45) 
were grouped together. The cancers, which, according to the International 
Agency for Research on Cancer (138) are affected by alcohol, included cancers 
of the oral cavity (C01C08), pharynx (C09C14), oesophagus (C15), colon 
(C18), rectum (C19C21), liver (C22), larynx (C32) and female breast (C50). 
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The smoking-related cancers included cancers of the oral cavity (C01C08), 
pharynx (C09C14), oesophagus (C15), stomach (C16), colon (C18), rectum 
(C19C21), liver (C22), pancreas (C25), nose and sinuses (C30C31), larynx 
(C32), bronchus and the lungs (C34), cervix uteri (C53), ovary (C56) and urinary 
organs (C64C68) and myeloid leukaemia (C92) (138). 
The data on gross domestic product (GDP) per capita in purchasing power 
standards were obtained from Eurostat (139) and expressed in current inter-
national dollars (II). 
To analyse the risk factors for disease recurrence (III), the variables were 
arranged into five groups: 1) demographic and socio-economic factors that 
included sex, age, place of birth, marital status, education, housing, employment 
status, history of imprisonment and health insurance; 2) factors related to 
baseline clinical history that included the way of case finding, i.e. active case 
finding by the health care workers or passive case finding or self-referral by the 
patient, time from the diagnosis to current treatment, history of previous use of 
anti-TB drugs, belonging to the group of chronic patients, TB localization, 
bacteriological status at the time of diagnosis, and presence or absence of a 
cavity in the lungs; 3) drug-resistance stratified by individual drugs (including 
resistance to ETM, OFX and thioamides and resistance to all three second-line 
injectable agents); 4) different resistance groups (including the total number of 
resistant drugs tested, XDR-TB and MDR-TB); 5) factors related to treatment 
that included duration of treatment in months, inclusion of an injectable agent 
into the regimen, SLDs being stopped due to the side effects, the number of 
drugs given in the intensive phase, the number of drugs given in the conti-
nuation phase and inclusion of any of the following drugs: a fluorquinolone, 
thioamide, CS, PAS or Z into the regimen. 
Codes of the International Statistical Classification of Diseases and Related 
Health Problems, 10th revision (ICD-10), were used for assessing the excess 
mortality and causes of death of subjects (IV) as well as for assessing the risk 
factors contributing to TB recurrence (III). 
The TB-related data for the round table article (I) for identification of main 
barriers to reaching the targets for TB control were taken from the literature, 
including WHO reports on TB, M/XDR-TB and HIV/AIDS (13, 18, 19, 23, 24, 
26, 31, 39, 42, 43, 61, 130, 131, 140-144) and ETR. 
 
4.6. Statistical analysis 
For analysing the data for the three Estonia-based Papers (IIIV), the SPSS® 
statistical package, version 17.0 (Statistical Package for Social Sciences, 
Chicago, IL, USA), was used. The Visual FoxPro 6.0 (Microsoft Corporation, 
Redmond, WA, USA) and Stata 10 (StataCorp LP, College Station, TX, USA) 
were used to calculate the excess mortality and determine the causes of death of 
all patients diagnosed alive with new respiratory TB (IV). In case of missing 
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data, the analyses were performed only for the cases with complete sets of 
information. 
Time trends in the overall notification rates and notification rates of culture 
confirmed pulmonary TB were tested using the Cochran-Armitage test for trend 
(II). Linear regression analysis was used to assess the impact of the availability 
of the SLDs and changes in GDP per capita on the change in yearly TB noti-
fication rates, as well as to evaluate the influence of HIV infection on the PTB 
and M/XDR-TB notification rates (II). 
Cox regression analysis with the Wald statistical criteria and backward 
elimination method were used to estimate the predictors of TB recurrence and 
mortality among all diagnosed M/XDRTB patients as well as among success-
fully treated ones (III). Both univariate and multivariate analyses stratified by 
XDR-TB patients were performed. To demonstrate the probability of TB 
recurrence, the Kaplan-Meier method was used, whereas the difference between 
strata was assessed with Breslow’s test (III). 
The SMR was calculated for males and females separately by dividing the 
observed number of deaths by the expected number of deaths (IV). The 
expected number of deaths in the cohorts was calculated by multiplying the age- 
and sex-specific person-years by the corresponding national mortality rates. The 
calculation was stratified by two calendar periods, 20022006 and 20072011. 
The 95% CI for SMR was calculated assuming a Poisson distribution for the 
observed deaths. Multivariate Poisson regression models were used to estimate 
the effect of age (4564 vs. 2544 years), education (basic or less vs. higher or 
secondary), ethnicity (non-Estonian vs. Estonian) and MDR-TB (MDR-TB vs. 
non-MDR-TB) on the risk of death. 
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5. RESULTS 
The main results of Papers IIV are summarised in this section. In Paper I the 
barriers to reach the targets laid out for global TB control were assessed by 
WHO regions. Paper I enabled to placing Estonia in the context of global TB 
and M/XDR-TB control. Paper II assessed the TB and MDR-TB notification 
trend and selected determinants of disease. Treatment outcome and disease 
recurrence of M/XDR-TB were the subject of the Paper III. Paper IV analysed 
the overall and cause-specific mortality among TB and M/XDR-TB patients as 
compared to the general population.  
 
 
Paper I 
By the end of 2004, 83% of the world’s population lived in countries or parts of 
countries covered by DOTS. Treatment success among 1.7 million DOTS pa-
tients notified in 2003 averaged 82%, which was close to the 2005 global target 
of 85%. However, the treatment success was below average in the African 
Region (72%), as well as in the European Region (75%). The main identified 
barrier to reach the global target was TB/HIV co-infection in the WHO African 
Region and drug-resistance in the WHO European Region (130).  
In 2004, Estonia belonged to the top ten countries or areas with the highest 
proportion of MDR-TB among never-previously-treated cases (12.2%) (Figure 
6). In addition to Estonia, five more high-MDR-TB-prevalence countries or 
regions originated from the former Soviet Union: Kazakhstan (14.2%); the 
Tomsk oblast in the Russian Federation (13.7%); Karakalpakstan, Uzbekistan 
(13.2%); Lithuania (9.4%) and Latvia (9.3%) (130, 145). The reported highest 
values of MDR-TB among previously treated cases were in Oman (58.3%) and 
Kazakhstan (56.4%), followed by Lithuania (53.3%), Estonia (45.3%), the 
Tomsk oblast in the Russian Federation (43.6%), the Orel oblast in the Russian 
Federation (42.4%), Karakalpakstan in Uzbekistan (40.2%), Egypt (38.2%) and 
Henan in China (36.6%) (130, 145).  
Estonia was one of the five first GLC-approved countries for management of 
MDR-TB. The treatment success among the first 46 MDR-TB patients enrolled 
for treatment from August 1, 2001 through December 31, 2001 was 65.2% 
(30/46). Meanwhile, the pooled treatment success of the first five GLC-
approved projects (Estonia, Latvia, Manila in the Philippines and the Tomsk 
oblast in the Russian Federation) was as high as 70%, or 78% among the never 
previously treated patients and 69% among previously treated patients (61). 
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Figure 6. Prevalence of multidrug-resistant tuberculosis (MDR-TB) in the ten countries or 
areas with the highest MDR-TB prevalence. RF: Russian Federation (modified from I).  
 
 
Paper II 
A total of 5,196 new and relapse pulmonary cases were included in the study, of 
whom 3,725 (71.7%) were males. The mean age of all subjects was 45.9 years. 
A total of 3,862 study subjects (74.3%) had DST results. Of those with the 
available DST results, 760 cases (19.7%) were diagnosed as having MDR-TB. 
Starting in 2000, 541 of MDR-TB strains (98.8%) were tested against SLDs and 
of theses, 95 (17.6%) were confirmed as having XDR-TB. Since 2001, 99.6% 
of patients (3,033 of 3,045) have been tested for HIV and of these, 132 (4.4%) 
have been HIV-positive. 
During the period 1998–2006 the incidence of TB decreased from 
59.2/100,000 in 1998, when the NTP was launched, to 32.7/100,000 in 2006, 
resulting in a mean annual decrease of 3.3 cases/100,000 or 7.02% (P=0.007). 
During the same period, the notification rate of M/XDR-TB decreased from 6.7 
to 3.5/100,000, resulting in a mean annual decrease of 1.7 cases/100,000 (5.5% 
yearly, P=0.008). During the whole study period (19982006), a significant 
increase in GDP per capita occurred, together with a lowering of the notification 
rate of overall TB, as well as that of MDR-TB (P<0.001 and P<0.001, 
respectively) (Figure 7). At the same time, there was an increase in TB/HIV co-
infection, which had a negative impact on the notification rates (P<0.001 and 
P=0.001, respectively) (Figure 8). 
The availability of SLDs after 2002 did not have any significant impact on 
the case notification rates of M/XDR-TB as compared to the previous period 
(1998–2001). However, there was a significant accelerating impact of the 
availability of SLDs on the decline in the annual notification (Figure 9).  
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During 1998–2006 the mean treatment success rate among all PTB cases in-
creased from 72.7% to 77.4% (P=0.009), whereas there was a decrease among 
the MDR-TB cases, from 54.8% to 51.1% (P=0.018). Meanwhile, the mean 
pooled treatment success of XDR-TB (47.7%) was much lower than that of all 
PTB and MDR-TB patients. Due to the low number of XDR-TB cases, it was 
not possible to analyse the treatment success over the years. 
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Figure 7. Notification rate of overall (new and relapses) culture-confirmed pulmonary 
tuberculosis (PTB) and multidrug-resistant TB (MDR-TB) in correlation with the Gross 
Domestic Product (GDP) per capita expressed in current international dollars per year in 
Estonia, 19982006. One international dollar equals one USD at a given point in time 
(modified from II).  
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Figure 8. Notification rate of overall (new and relapses) culture-confirmed pulmonary 
tuberculosis (PTB) and multidrug-resistant tuberculosis (MDR-TB) patients in corre-
lation with that of TB and human immunodeficiency virus (HIV) co-infection in Esto-
nia, 19982006 (modified from II).  
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Figure 9. Time trends in the notification rates of culture-confirmed pulmonary tuber-
culosis (TB) in Estonia, 19982006, before and after second-line drugs (SLD) became 
available in 2002: A) for multidrug-resistant TB (MDR-TB) and B) for overall pulmo-
nary TB. The time trends, tested by the Cochran-Armitage test, were non-significant for 
MDR-TB and overall pulmonary TB during both tested periods (19982001 and 
20022006). Linear regression analysis using the availability of SLDs as a covariate 
showed a significant accelerating impact on the down-going trends in MDR-TB 
(P=0.025), as well as in overall pulmonary TB (P=0.003) (modified from II).  
 
 
Paper III 
A total of 211 patients diagnosed with MDR-TB during the period from August 
01, 2001 through July 31, 2003, were included; out of these 43 patients had 
XDR-TB. The median age of all subjects was 42.9 years (range 17–76), 154 
(73.0%) were males and 172 (81.5%) were Estonians. A total of 5 (2.5%) HIV-
positive cases were diagnosed out of the 197 subjects tested for HIV infection. 
The treatment was successfully completed by 129 patients (61.1%). Treatment 
success among the MDR-TB and XDR-TB patients was 63.1% and 53.5%, 
respectively. The median duration of treatment among the successfully treated 
patients was 19.8 months (range 6.1–53.7). Out of all successfully treated 
patients, 11 (8.5%) had relapsed by the end of the follow-up time. A total of 82 
patients (38.9%), including 20 patients with XDR-TB, had a poor treatment 
outcome: 47 (22.3%) defaulted, 18 (8.5%) failed treatment and 17 (8.1%) died.  
The median follow-up time of all study subjects from the start of treatment 
with SLDs until the disease recurrence, death, emigration, or December 31, 
2010, whichever date was earlier, was 98.1 months (range 2.1–125.7 months). 
By the end of the observation period, 38 patients (18.0%) had died of TB and 23 
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(10.9%) of other reasons. The cumulative recurrence-free survival was lower 
among XDR-TB patients than among MDR-TB patients (P=0.012) (Figure 10).  
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Figure 10. Cumulative probability of tuberculosis (TB) recurrence-free survival of the 
211 multidrug-resistant- and extensively drug-resistant TB (M/XDR-TB) patients, who 
started treatment in Estonia, 01.08.200131.07.2003, stratified by XDR-TB (n=43) and 
MDR-TB patients (n=168). Reproduced with permission from III. 
 
Figure 11. Cumulative probability of tuberculosis (TB) recurrence-free survival of the 
129 successfully treated multidrug-resistant- and extensively drug-resistant TB 
(M/XDR-TB) patients, who started treatment in Estonia, 01.08.200131.01.2003, strati-
fied by XDR-TB (n=23) and MDR-non-XDR-TB (n=106). Reproduced with permission 
from III. 
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There was no difference between the 129 successfully treated XDR-TB (n=43) 
and MDR-TB patients (n=168) in terms of the cumulative recurrence-free 
survival (Figure 11). The median time to TB recurrence was 70.1 months (range 
32.3106.9). However, the probability of recurrence peaked during the period 
from year 5 to year 7 (63.6%) of follow-up. Of all patients with a successful 
treatment outcome, 118 (91.5%) remained without active TB, eight (6.2%) died 
of other reasons; 11 (8.5%) had a TB recurrence. 
In a multivariate model the risk factors associated with TB recurrence for all 
included patients were male sex, birth outside Estonia, history of previous anti-
TB treatment, sputum smear positivity at the beginning of treatment, resistance 
to 4 anti-TB drugs, resistance to all three second-line injectable and the 
absence of an injectable agent from the treatment regimen (P<0.05 for all). On 
the other hand inclusion of PAS in the regimen and a greater number of drugs 
given during the continuation phase of treatment appeared to be protective 
against TB recurrence (P<0.05) (Table 2). 
Among all successfully treated patients, only a history of previous TB treat-
ment was a risk-factor for TB recurrence (HR 4.28, 95% CI 1.1316.15, 
P=0.032). The median length of treatment among the 11 patients, who later 
developed TB recurrence, was 20.2 months (range 18.236.2); the difference 
was not statistically significant for those 118 patients who stayed TB free 
(median 19.7 months; range 6.153.7). 
In a multivariable model, including all 43 XDR-TB patients, male sex 
(P=0.007), birth outside Estonia (P=0.041), a history of previous anti-TB 
treatment (P<0.001), sputum-smear-positivity at the start of treatment with 
SLDs (P=0.021), resistance to 4 TB drugs (P=0.033) and the absence of an 
injectable drug from the treatment regimen (P=0.009) were found to have a 
negative impact on TB recurrence, whereas the higher number of anti-TB drugs 
given during the continuation phase (P<0.001), the presence of PAS (P=0.010) 
and OFX (P=0.037), and non-interruption of any of the SLDs due to their side 
effects (P=0.029) were protective against recurrence (Table 2). No significant 
risk factors were found, when the covariates were stratified by XDR-TB among 
the 129 successfully treated patients in a multivariable model. 
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Paper IV 
A total of 2,449 patients, 1,777 (72.6%) males and 674 (27.5%) females with 
newly diagnosed respiratory TB and M/XDR-TB were included in this study 
(Figure 5). Out of all study subjects 321 (13.1%) were diagnosed with M/XDR-
TB, of whom 224 (69.8%) were males and 97 (30.2%) females. A total of 34 
cases were diagnosed with XDR-TB. Out of the 2,210 subjects tested for HIV-
infection, 131 (5.9%) were positive. The mean age of the males was 44.3 
(standard deviation, SD 10.0 years) and that of the included females 42.2 (SD 
10.9 years). More than half (54.2%) of the subjects were Estonians, the majority 
with secondary or lower education (93.1%) and confirmed as having non-MDR-
TB (64.6%). During the overall follow-up period, a total of 661 (27.0%) 
patients died. A total of 2,013 (82.2%) were successfully treated and 182 (7.4%) 
died during TB treatment, of whom 63.8% were males (95 out of 149) and 
63.6% females (21 out of 33) who died from TB. The treatment success among 
males with non-MDR-TB was 84.3% and among males with MDR-TB 56.3%, 
whereas the respective figures among females were 86.3% and 68.0%.  
The notification rate of new respiratory TB stratified by age groups was 
higher among males than among females (Figure 12). In both Cohort 1 and 
Cohort 2 the difference in female mortality from all causes vs. the general 
female population was larger than the difference in male mortality from all 
causes vs. the general male population; the SMR was 10.0 and 6.24 among 
females and 5.3 and 3.46 among males, respectively. 
 
Cohort 1 (males with new respiratory TB)  
During the follow-up period, 535 deaths (8,858 person-years; average follow-up 
time 5.0 years) occurred among 1,775 males diagnosed with new respiratory TB 
compared to the expected 100.99 (SMR 5.30; 95% CI 4.855.75) (Table 3). 
0
10
20
30
40
50
60
70
80
90
100
25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64
Age groups
R
at
e 
/ 1
00
,0
00
 p
op
ul
at
io
n
 
Figure 12. Notification rate among the study IV patients diagnosed with new respira-
tory tuberculosis in Estonia, 20022009. 
Females 
Males 
 
49
 
Ta
bl
e 
3.
 O
bs
er
ve
d 
nu
m
be
r o
f d
ea
th
s a
nd
 st
an
da
rd
iz
ed
 m
or
ta
lit
y 
ra
tio
 (S
M
R
) w
ith
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
 (C
I)
 a
m
on
g 
pa
tie
nt
s d
ia
gn
os
ed
 w
ith
 
ne
w
 re
sp
ira
to
ry
 tu
be
rc
ul
os
is
 (C
oh
or
t 1
), 
Es
to
ni
a,
 d
ia
gn
os
ed
 d
ur
in
g 
th
e 
pe
rio
d 
01
.0
1.
20
02
–3
1.
12
.2
01
1 
(m
od
ifi
ed
 fr
om
 IV
) 
IC
D
-1
0 
C
au
se
 o
f d
ea
th
 
M
al
es
 
Fe
m
al
es
 
 
 
D
ea
th
s 
SM
R
 
95
%
 C
I 
D
ea
th
s 
SM
R
 
95
%
 C
I 
A
00
–Y
98
 
A
ll 
ca
us
es
 
53
5 
5.
30
 
4.
85
– 
   
5.
75
 
12
6 
10
.0
0 
8.
25
– 
 1
1.
74
 
A
15
–A
16
 
R
es
pi
ra
to
ry
 tu
be
rc
ul
os
is
 
13
7 
14
7.
69
 
12
2.
96
–1
72
.4
2 
29
 
45
9.
67
 
30
7.
85
–6
60
.1
6 
B
20
–B
24
 
H
IV
 d
is
ea
se
 
30
 
58
.2
4 
39
.3
0–
  8
3.
14
 
11
 
16
5.
78
 
82
.7
5–
29
6.
63
 
C
01
–C
15
, C
18
–C
22
, 
C
32
, C
50
 
A
lc
oh
ol
-r
el
at
ed
 c
an
ce
rs
1  
19
 
4.
06
 
2.
44
– 
   
6.
34
 
6 
4.
02
 
1.
47
– 
   
8.
74
 
C
01
–C
16
, C
18
–C
22
, 
C
25
, C
30
–C
32
, C
34
, 
C
53
, C
56
, C
64
–C
68
, 
C
92
 
Sm
ok
in
g-
re
la
te
d 
ca
nc
er
s2
 
50
 
3.
18
 
2.
36
– 
   
4.
20
 
13
 
5.
27
 
2.
81
– 
   
9.
01
 
I0
0–
I9
9 
D
is
ea
se
s o
f t
he
 c
irc
ul
at
or
y 
sy
st
em
 
86
 
2.
44
 
1.
95
– 
   
3.
02
 
16
 
4.
46
 
2.
55
– 
   
7.
24
 
J0
0–
J9
9 
D
is
ea
se
s o
f t
he
 re
sp
ira
to
ry
 
sy
st
em
 
23
 
5.
68
 
3.
60
– 
   
8.
53
 
10
 
30
.5
9 
14
.6
7–
  5
6.
25
 
J4
0–
J4
4 
C
hr
on
ic
 lo
w
er
 re
sp
ira
to
ry
 
di
se
as
es
 
5 
5.
88
 
1.
91
– 
 1
3.
73
 
3 
49
.8
5 
10
.2
8–
14
5.
68
 
K
00
–K
93
 
D
is
ea
se
s o
f t
he
 d
ig
es
tiv
e 
sy
st
em
 
34
 
4.
79
 
3.
32
– 
   
6.
70
 
17
 
16
.0
7 
9.
36
– 
 2
5.
74
 
V
01
–Y
98
 
Ex
te
rn
al
 c
au
se
s  
10
4 
4.
59
 
3.
71
– 
   
5.
48
 
13
 
7.
80
 
4.
15
– 
 1
3.
33
 
 
 
 
 
 
 
 
 
F1
0,
 I4
2.
6,
 K
70
, X
45
 
Se
le
ct
ed
 a
lc
oh
ol
-r
el
at
ed
 c
au
se
s 
57
 
4.
85
 
3.
67
– 
   
6.
28
 
20
 
16
.2
8 
9.
94
– 
 2
5.
14
 
1 A
m
on
g 
al
co
ho
l-r
el
at
ed
 c
an
ce
rs
, b
re
as
t c
an
ce
r (
C
50
) w
as
 a
pp
lic
ab
le
 o
nl
y 
fo
r f
em
al
es
. 2
 A
m
on
g 
sm
ok
in
g-
re
la
te
d 
ca
nc
er
s 
th
e 
ca
nc
er
s 
of
 c
er
vi
x 
ut
er
i (
C
53
) a
nd
 o
va
ry
 (C
56
) w
er
e 
ap
pl
ic
ab
le
 o
nl
y 
fo
r f
em
al
es
. I
C
D
-1
0:
 In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 D
is
ea
se
s 
an
d 
R
el
at
ed
 H
ea
lth
 P
ro
bl
em
s, 
ve
rs
io
n 
10
. 
 
  
 
50
 
Ta
bl
e 
4.
 O
bs
er
ve
d 
nu
m
be
r o
f d
ea
th
s a
nd
 st
an
da
rd
iz
ed
 m
or
ta
lit
y 
ra
tio
 (S
M
R
) w
ith
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
 (C
I)
 a
m
on
g 
su
cc
es
sf
ul
ly
 tr
ea
te
d 
pa
tie
nt
s w
ith
 n
ew
 re
sp
ira
to
ry
 tu
be
rc
ul
os
is
 (C
oh
or
t 2
) i
n 
Es
to
ni
a,
 d
ia
gn
os
ed
 d
ur
in
g 
th
e 
pe
rio
d 
01
.0
1.
20
02
3
1.
12
.2
01
1 
(m
od
ifi
ed
 fr
om
 IV
) 
IC
D
-1
0 
C
au
se
 o
f d
ea
th
 
M
al
es
 
Fe
m
al
es
 
 
 
D
ea
th
s 
SM
R
 
95
%
 C
I 
D
ea
th
s 
SM
R
 
95
%
 C
I 
A
00
–Y
98
 
A
ll 
ca
us
es
 
31
8 
3.
46
 
3.
08
– 
 3
.8
4 
70
 
6.
24
 
4.
86
– 
   
7.
88
 
A
15
–A
16
 
R
es
pi
ra
to
ry
 tu
be
rc
ul
os
is
 
32
 
38
.5
0 
26
.3
4–
54
.3
6 
1 
17
.9
7 
0.
45
– 
 0
0.
10
 
B
20
–B
24
 
H
IV
 d
is
ea
se
 
14
 
30
.4
9 
16
.6
7–
51
.1
6 
4 
65
.4
8 
17
.8
4–
16
7.
66
 
C
01
–C
15
, C
18
–C
22
, 
C
32
, C
50
 
A
lc
oh
ol
-r
el
at
ed
 c
an
ce
rs
1  
15
 
3.
48
 
1.
95
– 
 5
.7
4 
6 
4.
51
 
1.
66
– 
   
9.
82
 
C
01
–C
16
, C
18
–C
22
, 
C
25
, C
30
–C
32
, C
34
, 
C
53
, C
56
, C
64
–C
68
, 
C
92
 
Sm
ok
in
g-
re
la
te
d 
ca
nc
er
s2
 
36
 
2.
49
 
1.
74
– 
 3
.4
4 
10
 
4.
56
 
2.
18
– 
   
8.
38
 
I0
0–
I9
9 
D
is
ea
se
s o
f t
he
 c
irc
ul
at
or
y 
sy
st
em
 
66
 
2.
04
 
1.
58
– 
 2
.6
0 
15
 
4.
70
 
2.
63
– 
   
7.
75
 
J0
0–
J9
9 
D
is
ea
se
s o
f t
he
 re
sp
ira
to
ry
 sy
st
em
 
17
 
4.
63
 
2.
69
– 
 7
.4
1 
7 
23
.9
8 
9.
64
– 
 4
9.
41
 
J4
0–
J4
4 
C
hr
on
ic
 lo
w
er
 re
sp
ira
to
ry
 d
is
ea
se
s 
4 
5.
07
 
1.
38
–1
2.
98
 
2 
37
.3
3 
4.
52
– 
 3
4.
83
 
K
00
–K
93
 
D
is
ea
se
s o
f t
he
 d
ig
es
tiv
e 
sy
st
em
 
28
 
4.
36
 
2.
90
– 
 6
.3
0 
13
 
13
.8
2 
7.
36
– 
 2
3.
63
 
V
01
–Y
98
 
Ex
te
rn
al
 c
au
se
s  
75
 
3.
69
 
2.
90
– 
 4
.6
2 
7 
4.
71
 
1.
89
– 
   
9.
71
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F1
0,
 I4
2.
6,
 K
70
, X
45
 
Se
le
ct
ed
 a
lc
oh
ol
-r
el
at
ed
 c
au
se
s 
40
 
3.
78
 
2.
70
– 
 5
.1
4 
16
 
14
.6
7 
8.
39
– 
 2
3.
83
 
1  A
m
on
g 
al
co
ho
l-r
el
at
ed
 c
an
ce
rs
, b
re
as
t c
an
ce
r (
C
50
) w
as
 a
pp
lic
ab
le
 o
nl
y 
fo
r f
em
al
es
. 2
 A
m
on
g 
sm
ok
in
g-
re
la
te
d 
ca
nc
er
s 
th
e 
ca
nc
er
s 
of
 c
er
vi
x 
ut
er
i (
C
53
) a
nd
 o
va
ry
 (C
56
) w
er
e 
ap
pl
ic
ab
le
 o
nl
y 
fo
r f
em
al
es
. I
C
D
-1
0:
 In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 D
is
ea
se
s 
an
d 
R
el
at
ed
 H
ea
lth
 P
ro
bl
em
s, 
ve
rs
io
n 
10
. 
  
 51
A total of 137 men died of respiratory TB. Mortality was increased in all 
groups of causes of death assessed: due to HIV disease (SMR 58.24; 95% CI 
39.3083.14), external causes of death (SMR 4.59; 95% CI 3.715.48), neo-
plasms, including alcohol-related (SMR 4.06; 95% CI 2.446.34) and smoking-
related cancers (SMR 3.18; 95% CI 2.364.20) and selected alcohol-related 
causes (SMR 4.85; 95% CI 3.676.28). There was also an excess mortality due 
to the diseases of the respiratory (SMR 5.86; 95% CI 3.608.53), digestive 
(SMR 4.79; 95% CI 3.326.70) and circulatory (SMR 2.44; 95% CI 1.953.02) 
systems. 
Being diagnosed with MDR-TB increased the relative risk of death due to 
respiratory TB (ARR 2.98; 95% CI 2.00–4.44). Furthermore, the relative risk of 
all cause mortality was higher among cases with MDR-TB compared to those 
with non-MDR-TB (ARR 1.58; 95% CI 1.24–2.02). Older persons, persons of 
foreign ethnicity or with a lower level of education had a relatively higher risk 
of all cause mortality and mortality due to respiratory TB.  
 
Cohort 1 (females with new respiratory TB)  
A total of 126 deaths (3,806 person-years; average follow-up time 5.6 years) 
occurred among 674 females diagnosed with new respiratory TB, compared to 
the expected 12.60 deaths (SMR 10.00; 95% CI 8.2511.74) (Table 3). A total 
of 29 females died due to respiratory TB. As with males, there was an increased 
mortality in all assessed groups of causes of death. The mortality was notably 
increased due to HIV disease (SMR 165.78; 95% CI 82.75296.63), but also 
due to external causes of deaths (SMR 7.80; 95% CI 4.1513.33), selected 
alcohol-related causes of death (SMR 16.28; 95% CI 9.9425.14), neoplasms, 
including smoking-related cancers (SMR 5.27; 95% CI 2.819.01) and alcohol-
related cancers (SMR 4.02; 95% CI 1.47–8.74), along with diseases of the 
respiratory, digestive and circulatory systems (Table 3). 
The relative risk of death due to respiratory TB among females increased in 
cases of MDR-TB compared to those of non-MDR-TB and bacteriologically 
non-confirmed TB (ARR 3.26; 95% CI 1.427.50). The all cause mortality and 
mortality due to respiratory TB was increased in cases were the subjects were of 
foreign ethnicity (ARR 1.94; 1.632.32 and ARR 2.38; 95% CI 1.693.37, 
respectively) or older than 45 years of age (ARR 1.97; 1.652.35 and ARR 
2.02; 95% CI 1.422.88, respectively). A lower level of education conveyed 
increased risk of all cause mortality (ARR 1.65; 95% CI 1.31.96). 
 
Cohort -2 (successfully treated males)  
A total of 318 deaths (7,950 person-years, average follow-up time 5.5 years) 
occurred among the 1,438 successfully treated males, compared to the expected 
92.01 deaths (SMR 3.46; 95% CI 3.083.84). A total of 32 deaths occurred due 
to TB. The excess mortality was observed in all assessed groups of causes of 
death, although the SMRs were smaller than in Cohort 1 (Table 4). 
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Across the sub-groups of successfully treated males, having had MDR-TB 
did not increase the relative risk of all cause mortality as compared to the non-
MDR-TB patients. As with Cohort 1, foreign ethnicity (ARR 1.65; 95% CI 
1.322.07), lower level of education (ARR 1.44; 95% CI 1.151.78) and older 
age (ARR 2.00; 95% CI 1.582.53) increased the all cause mortality. 
 
Cohort 2 (successfully treated females)  
A total of 70 deaths (3,420 person-years, average follow-up time 6.0 years) 
occurred among the successfully treated 575 females as compared to the 
expected 11.22 deaths (SMR 6.24; 95% CI 4.867.88). One person died due to 
respiratory TB. The excess mortality was observed in most of the assessed 
groups of causes of deaths; however, as among the males, the SMRs were lower 
than in Cohort 1 (Table 4).  
Having successfully treated MDR-TB did not increase the relative risk of all 
cause mortality compared to the non-MDR-TB patients. Foreign ethnicity (ARR 
1.87; 95% CI 1.173.01) or older age (ARR 4.03; 95% CI 2.366.87) were 
associated with higher risk of all cause mortality among females.  
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6. DISCUSSION 
The aim of the chapter is to discuss the findings of all four papers as a whole as 
to answer the main study question, i.e. the impact of M/XDR-TB on the TB 
notification rate, disease recurrence and mortality, rather than to discuss sepa-
rately the interlinked specific findings of the four studies. 
In Estonia, as elsewhere, M/XDR-TB is a man-made phenomenon (IIV). 
Starting in the 1990s the TB incidence began to increase and reached the 
highest rates in 1998 when the NTP was established. In fact, in Estonia it was 
not merely a TB epidemic, but rather a combined TB and M/XDR-TB epidemic 
(IIV) as is also shown in the studies by Lockman et al. and in WHO reports 
(13, 93). One of the main barriers to reach the Stop TB targets in the European 
Region, which Estonia is part of, is the high proportion of difficult-to-treat 
MDR-TB (I). Historically, the incidence of TB and M/XDR-TB has been 
influenced by clinical factors along with the socio-economic conditions and 
HIV infection. Does this still hold true for contemporary Estonia?  
 
 
6.1. TB and M/XDR-TB incidence (IIV) 
Poverty (II) 
In order to assess the association between poverty and TB, we used GDP per 
capita, available from 1998, as an indicator of deprivation (II). We found that, 
while the GDP was gradually increasing, the TB and M/XDR-TB incidence 
decreased, particularly after 2002, when a decade had passed after the sharp 
economic and political changes occasioned by the break-up of the Soviet Union. 
However, the association between TB and poverty is complex and social 
conditions have a strong influence on the spread of TB infection on the one 
hand and defence mechanisms of the host on the other (1). There is a variety of 
indexes for grading poverty, each encompassing different factors. In 2005, the 
GDP per capita has been used to assess deprivation among European Union 
countries by Fahey et al. (146). In a different paper Fahey (147) outlines the 
concept of complex and simple relative deprivation. British studies confirmed a 
strong association between TB and poverty in Liverpool in the 1980ʹs and in 
metropolitan areas of London in the 1990ʹs by using the Jarman and Townsend 
simple deprivation indices (148, 149). Based on our current findings, we can 
conclude that the future of TB epidemics in Estonia depends partly on the 
economic development of the country.  
 
TB and HIV and M/XDR-TB co-infection (IIV) 
We have currently confirmed that HIV has a major impact on TB and M/XDR-
TB epidemics in Estonia (I). This has also been proven for high-HIV prevalence 
areas, such as Southern and Eastern Africa (2). In 2001, there was an upsurge of 
TB/HIV co-infection in Estonia (IIIV), which significantly heightened TB 
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incidence (II). Furthermore, we confirmed an excess mortality due to AIDS 
among new respiratory TB and M/XDR-TB cases during, as well as after, 
successful treatment of TB (IV). There is sufficient evidence from other 
researchers to support the concept of the deadly liaison of TB and HIV in the 
European region (150). It is known that HIV infection suppresses the cell-
mediated immunity contributing to the susceptibility of the co-infected person 
to TB (48, 151). HIV infection also increases the progression and severity of TB 
by impairing granuloma formation and recruitment of CD4 lymphocytes into 
the lungs and elaboration of cytokines by bronchoalveolar immunocompetent 
cells (48, 151). On the other hand, TB leads to an increase in the viral load in 
HIV-infected persons by activating innate adaptive signalling cascades that 
stimulate HIV-1 replication (151). In context with the high mortality rate among 
HIV-infected patients with XDR-TB, a hypothesis exists that the resistant TB 
bacteria, often considered to be of a lower relative fitness compared to drug 
sensitive strains, may still thrive well in the condition of immune suppression 
(32). In line with this view, since Estonia is one of the countries with the fastest 
growing HIV epidemics in the world (152), a significant increase in TB and 
M/XDR-TB incidence ought to occur in the nearest future unless more effort is 
made to decrease the occurrence and, thus, the co-occurrence of both diseases. 
 
National Tuberculosis Programme and treatment of TB and M/XDR-TB (IIII) 
Since 1998, the NTP has been implemented in Estonia to improve the 
management of TB and M/XDR-TB (IIIII). The cornerstones of the NTP are 
the countrywide access to good quality laboratory services and anti-TB drugs, 
including SLDs. The NTP is aligning its targets to the Stop TB Strategy 
announced in 2006, which aims at achieving at least 70% detection and an 85% 
cure rate (44). The new WHO targets for a treatment success rate by 2015 are 
even higher: 90% among TB cases and 75% among MDR-TB cases (5). 
Although the average treatment success for the global 2003 cohort was 82%, in 
the WHO European Region with high M/XDR-TB prevalence, it was only 75%. 
Thus, M/XDR-TB turns out to be the main barrier to reaching the target (I). By 
2010, the global treatment success among newly-diagnosed TB was already 
85%, but only 74% in the WHO European Region (2). 
The mean treatment success among all diagnosed pulmonary non-MDR-TB 
cases in Estonia was 80.8%, or 53.1% among MDR-TB cases but only 47.7% 
among XDR-TB cases (II). As expected, the treatment success among the 
selected MDR-TB and XDR-TB patients was higher, being 63.1% and 53.3%, 
respectively (III). It is estimated that the treatment success among M/XDR-TB 
cases has to be far above 50% to cut the transmission of infection and, therefore, 
to decrease the incidence (6). Although currently the number of XDR-TB 
patients in Estonia is still low, the suboptimal treatment success of these cases is 
of great concern as the likelihood of continued transmission of the XDR-TB 
infection in society is high. Not surprisingly, the treatment success among the 
XDR-TB patients has been reported to be lower than that of MDR-TB 
worldwide. In a meta-analysis of nine studies, the treatment success of the 
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XDR-TB cases ranged from 34% to 67% (153), while in a study from South 
Korea, the treatment success was reported to be as low as 18% (71). In a study 
from Peru (69) the treatment success of XDR-TB was 60.4% compared to 
66.3% among MDR-TB patients. For comparison, in a different study from 
Estonia (66), the treatment success among XDR-TB cases was 40.7%, close to 
what we found in our study (II). 
We found that the combined treatment success among selected M/XDR-TB 
patients that were treated with SLDs for longer than one month was 61.1% (III), 
which is rather similar to the success reported in two recent surveys: 62% (mean 
95% CI 57–67) among the 36 reviewed MDR-TB studies by Johnston et al. (62) 
and 64% (mean 95% CI 59–68%) among the 29 reviewed studies using 
individualized treatment regimens by Orenstein et al. (64). There are numerous 
reasons why the treatment success among M/XDR-TB patients is generally low: 
socio-economic, clinical, and managerial (154). The socio-economic factors 
have been extensively described in many countries, including in Estonia (115). 
This Estonian study showed that a history of imprisonment, alcohol abuse, 
being foreign born, being homeless and jobless and living in an urban area were 
predictors of poor treatment outcome among patients with pulmonary 
tuberculosis. The same factors were prominent in case of M/XDR-TB, where 
these mentioned risk factors are already operative for the development of 
M/XDR-TB in the first place, as is also shown by Faustini et al. (52). The low 
treatment success among M/XDR-TB patients in our study could have been 
influenced in part by the lengthy treatment that lasted more than 20 months 
(III), which possibly increases the defaulter rate. In our study (III), we 
concluded that the low treatment success was largely due to the high default rate 
(22.3%), rather than to the ineffectiveness of the treatment regimens. The 
ineffectiveness or/and toxicity of the treatment regimens would be presumably 
expressed by failure and death rates. The pooled proportion of those who died 
(8.1%) and those who failed (8.5%) in our study was 16.4%, which was less 
than the percentage of those who defaulted. The risk factors for default among 
TB and M/XDR-TB patients have been described in various settings in the 
world (154, 155) including in Estonia (115). Kliiman et al. found that the risk 
factors for default are largely socio-economic, i.e. urban residence, unemploy-
ment, alcohol abuse, and history of previous anti-TB treatment (115). 
We demonstrated that the implementation of the NTP in Estonia together 
with the other factors such as the increase in GDP, contributed to the 7.01% 
yearly decrease in the incidence of TB and 5.5% of M/XDR-TB (II). It is 
considered that in developing countries an effective TB programme could 
achieve 710% and exceptionally, even 15% of the yearly decrease in the TB 
notification rate (6). However, we found no studies assessing the average annual 
decrease in the M/XDR-TB notification rate globally, and the present study (II) 
evaluated it for the first time in Estonia. Despite our finding that the M/XDR-
TB incidence has decreased annually by 5.5% in Estonia, one might interpret 
this to be too low to achieve the global targets, especially as HIV infection is 
still on the rise and the relative fitness and following transmissibility of RMP-
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resistant mutant strains of M. tuberculosis in the society might not differ from 
that of drug-sensitive TB (32, 38). However, in case of a possible benign TB 
epidemic (36, 37), the earlier described treatment success among the non-MDR-
TB cases, as well as M/XDR-TB cases, has probably contributed to the 
observed decrease of the incidence of TB and M/XDR-TB in Estonia (II). 
 
Second-line anti-TB drugs (II, IV) 
The availability of SLDs in Estonia accelerated the decrease in incidence of TB, 
as well as that of M/XDR-TB (II). However, the introduction of the country 
wide availability of the SLDs after the first centralized procurement in 2001 did 
not have a significant additional impact on incidence of TB. The reason might 
be that the SLDs were to some extent available already before the centralized 
procurement, although not for full-course therapy. On the other hand, although 
prominent in Estonia, the proportion of M/XDR-TB cases is probably still too 
low to have a significant impact on the incidence in such a short time. The 
successful treatment of TB and M/XDR-TB depends, apart from other deter-
minants, also on the effectiveness of the treatment regimens. In our study (III) 
the older WHO recommendations (141) for treatment of M/XDR-TB were used; 
therefore, the treatment success might improve if the recommendations of the 
WHO MDR-TB guidelines published in 2011 (84) are applied. However, it is 
acknowledged that the currently used SLDs are generally less effective in the 
treatment of TB than FLDs (3, 6). There are several novel anti-TB drugs in the 
pipeline (156, 157), such as bedaquiline (158, 159) and delamanid (160). 
However, limited evidence is available regarding the role of these drugs in 
M/XDR-TB treatment.  
Evidence exists that the side effects of the FLDs (161), particularly in 
combination with anti-retroviral therapy (162), are contributing to the 
heightened default rate. Little is known about the exact magnitude of the effect 
of treatment with SLDs on the adherence to treatment; however, the multiple 
well-documented side effects of the SLDs (163168) and the long treatment 
duration of M/XDR-TB should not be underestimated. The effect of the SLDs 
on mortality during treatment and later on, after successfully completing the 
treatment, has not been studied. Currently, we found that among our study 
subjects (IV) mortality due to the diseases likely to be affected by the SLDs, 
such as gastrointestinal, hepatic, and cardio-vascular disturbances, cancers, was 
similarly increased not only among the diagnosed but also successfully treated 
TB and M/XDR-TB patients. This suggests a modest impact of the SLDs 
compared to the FLDs on the later mortality.  
 
 
6.2. TB recurrence and mortality (IIIV) 
To measure the long-term effectiveness of the M/XDR-TB treatment regimens, 
we analysed the TB recurrence and mortality after being diagnosed with MDR-
TB and after successful completion of the treatment (III). Among the M/XDR-
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TB patients, the cumulative disease-free survival was significantly lower in 
XDR-TB than in MDR-TB. However, among those patients who were 
successfully treated, the two cohorts did not differ from each other in terms of 
TB recurrence and mortality (III). More importantly, we demonstrated that after 
successful treatment, the risk of death among patients with M/XDR-TB did not 
increase compared to the patients with drug-sensitive TB (IV). In this light, our 
findings point out the paramount importance of achieving treatment success, 
whatever the resistance pattern is. This is also supported by the fact that after 
successful treatment, the risk factors for all cause mortality had a comparable 
effect in all three sub-groups, i.e. patients with a history of MDR-TB, non-
MDR-TB or bacteriologically non-confirmed TB (IV). 
In our study (III) TB recurrence occurred in 8.5% of M/XDR-TB patients 
over an 8-year follow-up period, which was also the longest follow-up period 
published so far. Lee et al. demonstrated that in a selected cohort of MDR-TB 
patients, the 2-year recurrence was 4.4% (10). In our study (III), the 2-year 
recurrence was even lower (Figure 11), suggesting that the treatment regimens 
used to treat M/XDR-TB in Estonia are reasonably effective. 
Paradoxically, we found that the previous anti-TB treatment had a significant 
negative impact on the disease recurrence among successfully treated M/XDR-
TB patients (III). The previous anti-TB treatment could be associated with 
possibly larger inflammatory damage of the lung tissue resulting in decreased 
lung reserve and scarring. This could affect the drug concentration in the 
affected area and, possibly, even the ability to kill all bacteria. On the other 
hand, it has also been shown that the retreatment cases are more prone to have 
boosted behavioural challenges that negatively influence their possible cure 
(169). 
Among all M/XDR-TB patients TB recurrence and later mortality were more 
likely to occur when the resistance of the pathogen to the anti-TB drugs was 
more extensive but also when there was a resistance to all three second-line 
injectable drugs or a resistance to PAS (III). Our current finding of PAS as an 
important agent in the treatment regimen differs from that in the meta-analysis 
of 9,153 patients by Ahuja et al. (116), where the use of just fluoroquinolones 
and thioamides were found to be important to achieve treatment success. 
Nonetheless, considering that the analysis by Ahuja et al. (116), as well as our 
study, was not blind, it is difficult to make a definite statement regarding the 
role of a particular drug. However, one may still conclude that the combination 
therapy has a prominent role in the treatment of M/XDR-TB. Complimentary to 
the aforementioned findings, the total number of anti-TB drugs used during the 
continuation phase of treatment was found to be significantly protective against 
disease recurrence (III), possibly due to the lower effectiveness of SLDs 
compared to that of FLDs (6, 170). However, being ill with XDR-TB did not 
result in a higher TB recurrence as compared to MDR-TB-non-XDR-TB among 
our study subjects (III). It can be reasoned that in the case of XDR-TB it would 
still be possible to compose a treatment regimen with an inclusion of an 
injectable agent of proven susceptibility (3, 84). On the other hand, the more 
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vulnerable hosts might have died during the treatment course, no matter what is 
the resistance pattern or the risk factors affecting the TB recurrence and later 
survival of the successfully treated patients (III, IV). In cases of XDR-TB, 
adding fluoroquinolone to the regimen, even if the pathogen was resistant to it, 
was still effective to avoid disease recurrence (III). This finding could be 
associated with 1) a different level of resistance among the bacterial population 
(25) in the affected tissue and 2) possible misinterpretation of the DST for SLDs 
in general and for fluoroquinolones in particular (171, 172). TB was more likely 
to recur among XDR-TB patients when any of the SLDs were stopped due to 
their side effects. This is understandable because of extensive resistance and 
loss of the benefits of combination therapy (18). The median length of treatment 
among those patients who later developed TB recurrence, as well as among 
those, who remained TB-free was approximately 20 months (III), which is 
similar to the finding by Ahuja et al. (116). Nowadays, there is no clear 
consensus about the duration of M/XDR-TB treatment with the currently 
available anti-TB drugs. Nine-month chemotherapy for MDR-TB patients has 
been piloted in Bangladesh with excellent results, 87.9% cure (173). However, 
the extent of drug-resistance prevailing in that pilot project was considerably 
lower than that in Estonia (IIV). Based on our findings (III), we can recom-
mend for treatment of M/XDR-TB in Estonia a ≥20 month combination therapy 
with a higher rather than with a lower number of second-line drugs in the 
intensive as well as in the continuation phase. 
 
Smear positivity at the start of treatment (III) 
Smear-positivity at the start of TB treatment was proven to be a risk factor for 
the disease recurrence in both MDR-TB and XDR-TB patients (III). Smear-
positivity has been found to be a significant predictor of disease recurrence in 
drug-susceptible TB without HIV infection (174, 175). Smear-positivity is 
linked to the severity of disease (176), which in turn may be associated with 
longer patient and/or health care related delay (177). Early case finding, early 
diagnosis and early commencement of the SLD treatment need to be enforced to 
prevent the recurrence of M/XDR-TB.  
 
Sex differences (III, IV) 
Along with numerous studies on TB patients (77, 9193), we currently found 
that male sex was an independent predictor of the disease recurrence and 
mortality among the M/XDR-TB patients in Estonia (III). The review by 
Holmes et al. (178) demonstrated that although in industrialized countries the 
prevalence of TB infection was almost equal among males and females below 
1016 years of age, the TB prevalence (179) as well as the notification rates 
(178) were initially higher among females up to 2434 years of age, but shifted 
towards increased notification rates among males older than 34 years. In 
Estonia, the notification rates among new respiratory TB cases in both sexes 
aged 25 to 64 years (IV) followed the trends similar to those found in low-
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income countries, for example in Tanzania during the period 19861991 (178). 
It is acknowledged that there are sex differences in TB, which are partly 
explained by socio-economic and cultural factors. It has been assumed that in 
low-income countries, there could be under-reporting among women due to 
social disparities and unequal access to health care facilities (178). This is 
apparently not a predominant cause in Estonia nor qualifies the country for a 
low-income definition by the World Bank. On the other hand, a survey 
comparing alcohol consumption in Estonia and Finland during the period 
19942006 found that alcohol consumption among Estonian males is estimated 
to be three times higher than among females (180). In our present study (IV), 
the all cause SMR among females was higher than that among males. It is 
possible that the life-style-associated risk factors for death have a stronger 
negative impact on females than males. Further studies are needed to compare 
the risk factors for TB disease and later mortality between males and females in 
Estonia. Alcohol abuse and tobacco smoking are widely acknowledged risk 
factors for TB infection, TB disease and mortality (100, 181183). 
While the socio-economic factors have been extensively explored, the role of 
biological sex differences such as the role of sexual hormones, sex-related 
genetic background and genetic regulations and metabolism is not clear (184, 
185) and necessitates further research.  
It is anticipated that when TB incidence falls in Estonia below 30/100,000, 
the sex-specific TB notification rates will follow those observed during the last 
40 years in industrialized countries (178), i.e. higher notification rates among 
younger females, similar rates in the age group 2534, followed by relatively 
higher rates among older males.  
 
Status of foreign birth (III, IV) 
Being foreign born increased the risk of TB recurrence and mortality among 
diagnosed pulmonary M/XDR-TB patients (III) and was a risk factor for all 
cause and TB-mortality among patients with respiratory TB (IV). It is con-
sidered that a period of 2–5 years is crucial for TB occurrence in immigrants 
(186) and has been attributed to socio-economic disparities in the host country 
(149). The country of origin is also important: a person born in a high-TB-
incidence country is more likely to be infected at the place of origin and has 
therefore a higher risk of developing TB. Furthermore, Weinstock (187) implies 
that chronic stress among immigrants has a manifold effect on the health in 
overall and immune system in particular. In our studies (III, IV) the foreign 
born persons have lived in Estonia more than 5 years, which may imply that the 
risk factors which have been operative during the first 25 years continue their 
influence later on in Estonia. Given global trends for migration it can be 
assumed that the proportion of immigrants will increase in Estonia as the GDP 
per capita increases in the country. Therefore, there is a need to develop a 
comprehensive public health policy (188) to address the health needs of this 
particular population group. 
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6.3. Causes of death (IV) 
The mortality of patients with respiratory TB and particularly that of respiratory 
M/XDR-TB was hundreds of times higher than that in the general population 
(IV). Unfortunately, the same was true even after the TB patients had success-
fully completed their treatment, although the treatment should presumably 
provide a stable cure. The important finding was that during an average follow-
up of more than 4 years (IV), the patients diagnosed with TB and MDR-TB also 
had an increased risk of all cause mortality in comparison to the general 
population (IV). In our study (IV), the risk of death following the diagnosis was 
higher among M/XDR-TB patients compared to the non-MDR-TB patients, 
which is in-line with the findings of other authors (189). 
There are only a few studies assessing SMR among the non-MDR-TB 
patients. However, we are unaware of country wide studies with as high a 
proportion of M/XDR-TB patients as has been the case in Estonia. Two studies 
from India with an average follow-up of 1.6 (92) and 3.3 (128) years, 
respectively, assessed mortality of DOTS patients and found a 4.2-fold and 6.1-
fold increase in all cause mortality, compared to the general population, 
respectively.  
 In our study, the all cause mortality remained higher compared to that of the 
general population even after successful treatment (IV). In a study from 
Liverpool which involved mainly non-MDR-TB patients an 11-fold excess 
mortality was found among successfully treated patients, compared to that in the 
general population (99). In a similar study from Ethiopia, 4.5-fold excess all 
cause mortality was found among TB cases after successful treatment (91). 
In our current study, we found no significant difference for the risk of death 
among the successfully treated M/XDR-TB compared to the successfully 
treated non-MDR-TB patients (IV). To our knowledge there are no comparable 
studies available. Our results may suggest that after successful treatment, the 
risk factors in TB and MDR-TB sub-groups have a comparable effect on the 
risk of mortality. Researchers from England (190) have found that after 
successful completion of TB treatment, the patients acquired a healthier lifestyle 
(i.e. with less smoking and alcohol consumption), which, although not yet 
addressed, might also be the case in Estonia.  
The excess mortality due to HIV disease among diagnosed, as well as 
successfully treated respiratory TB patients (IV), was not unexpected given the 
rapidly growing and decade-long HIV epidemic in Estonia. HIV infection is a 
well-known major risk factor for developing TB disease (50, 51), but also for 
death during (77, 100) and after TB treatment (100). 
We found increased mortality due to causes affected by smoking, such as 
neoplasms, diseases of the circulatory system (191), and chronic lower 
respiratory diseases (192). It has been shown that there is a significant risk of 
death due to cancer among smokers in Estonia (193). It is well established that 
smoking (11, 103, 105, 106, 109, 194) and alcohol abuse (100, 111) are 
determinants of TB disease. Alcohol abuse, but less clearly tobacco smoking are 
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contributing factors for the poor treatment outcome of TB patients (98, 100, 
110, 111, 194). Smoking has been implicated in reducing mucociliary clearance 
as well as in affecting the length of cilia in the airways (195). This mechanism 
could possibly also affect the innate defences of the host organism against M. 
tuberculosis (109). Furthermore, tobacco smoke is considered to turn off the 
production of TNF- by the macrophages in the lungs, thereby increasing the 
likelihood of the progression of an infection to TB disease (107, 196). The 
effect of smoking is well studied in the context of human cancers (138).  
In Paper IV, the mortality due to the diseases of the respiratory system, 
particularly chronic lower respiratory diseases, was significantly increased in 
comparison with the general population. Currently, tobacco smoke remains the 
primary risk factor for chronic lower respiratory diseases, including chronic 
obstructive pulmonary disease (COPD) (197). However, among non-smokers as 
well, COPD and chronic airflow obstruction is often considered to be a risk 
factor for PTB (192). On the other hand, PTB is identified as one of the 
predictors of COPD and chronic bronchitis (11, 192, 198200). The excess 
mortality due to smoking-related disease (IV), assuming the interaction between 
smoking and TB among study subjects, might be the cause of the increased 
mortality due to the chronic lower respiratory diseases in our study (IV). The 
possible mechanisms for chronic airflow obstruction after TB are airflow 
limitation as a consequence of lung scarring and bronchial stenosis. Further-
more, TB increases the activity of matrix metalloproteinases, which contribute 
to the damage of the alveolar tissue observed in COPD (192, 201, 202). On the 
other hand, factors like impaired mucociliary clearance and low body mass 
index affect cell-mediated immunity in COPD and may predispose occurrence 
of bacterial infections including also TB (192, 203). Nevertheless, the mecha-
nisms discussed are not completely understood, nor is the mechanism of HIV 
infection as a cause of pulmonary emphysema (204). Further studies are 
therefore needed to understand the complex interactions between TB, HIV, 
COPD, and tobacco smoking. 
In study IV, we grouped together the main alcohol-related causes of death 
(205), such as mental and behavioural disorders due to the use of alcohol, 
alcoholic cardiomyopathy, alcoholic liver disease, and accidental poisoning by 
alcohol. This was done due to the recognised misclassification of alcohol 
poisoning in the mortality statistics in Estonia (126). The excess mortality due 
to these causes was found among the males, but even more among the female 
subjects in comparison to the general population (IV). This finding and the fact 
that in our study (IV) only a third were women leads to the possibility that 
females are particularly vulnerable to life-style factors. The problem of alcohol 
abuse in Estonia in general (180) and among TB and MDR-TB patients in 
particular (115) has been identified by several authors. Expectedly, poverty, 
malnutrition and related diseases are rampant among alcohol abusers (205). 
Indeed, among the study subjects (IV), the mortality due to alcohol-related 
cancers (138) had increased. Furthermore, there was an excess mortality of the 
study subjects compared to that of the general population due to external causes 
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of death (IV), which are known to be alcohol-related (205, 206). Also, the 
mortality due to respiratory diseases was increased in our study (IV). As with 
TB, an increase in mortality from other lower respiratory tract infections, such 
as pneumonia, has been attributed to alcohol abuse (205). However, the exact 
extent to which the mortality due to respiratory diseases is attributed to alcohol 
has yet to be determined. 
The findings that both diagnosed and successfully treated TB and MDR-TB 
patients are at risk of dying from alcohol- and smoking-related causes (IV) 
highlights the importance of addressing the socio-economic drivers behind 
smoking and alcohol abuse.  
 
The level of education (IV) 
We found that an educational level lower than secondary was associated with a 
higher risk of mortality (IV). Lower education has been formally associated 
with both a higher risk of TB (100, 164) and poor treatment outcome (175). In a 
multinational study from 16 European countries, which included persons aged 
≤30 years, subjects with higher levels of education had significantly lower 
mortality rates (207). In a survey from Lithuania, survival of M/XDR-TB 
patients was influenced, apart from other factors, by a lower education level 
(208).  
 
Age (IV) 
We found currently that all cause mortality and mortality from TB increased 
with advancing age (IV). Higher age has been found to be a risk factor for death 
during anti-TB treatment in the majority of former studies (78, 80, 9496). In 
particular, the effect of higher age has been attributed to co-morbidities (100). 
However in our study it could as well have reflected limited access to health 
care services among older people in Estonia.  
 
The link between TB, HIV, tobacco smoking and alcohol and substance abuse 
epidemics is well established (11). Furthermore, smoking, alcohol abuse, 
educational status, and social marginalization are closely linked to malnutrition 
and poverty (51), as demonstrated also by the present studies from Estonia 
(IIIV). 
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7. CONCLUSIONS 
 One of the main barriers to reaching the global targets for TB control in 
Estonia, as well as internationally, is the high rate of M/XDR-TB. We found 
that in Estonia the TB and MDR-TB epidemic is closely connected to the 
HIV epidemic and interlinked with the higher mortality related to the 
lifestyle factors of tobacco smoking and alcohol abuse, as well as social 
factors such as educational status, social marginalization and poverty. To 
improve TB and M/XDR-TB management in general and the M/XDR-TB 
treatment outcome in particular, the TB-related service package should take 
into account all the listed challenges.  
 
 From 1998, the TB and M/XDR-TB incidence has decreased in Estonia in a 
close time relation to launching of the NTP, countrywide availability of the 
SLDs and growth of the wealth of the population. The increased prevalence 
of HIV infection during the last decade has fuelled an increase in the 
incidence of TB, which is anticipated to continue during the forthcoming 
years. To avoid colliding TB/HIV and even worse, a difficult-to-treat 
M/XDR-TB and HIV co-epidemic, it is crucial to decrease the TB incidence 
faster than the current annual decline of 7.07% and 5.5%, respectively.  
 
 An effort should be made by the health care services in Estonia to improve 
the treatment outcome of M/XDR-TB patients to that of the WHO-
recommended 75%. The proportion of successfully treated M/XDR-TB 
patients within the first GLC-approved project was as low as 61.1%, mainly 
due to the high proportion of defaulters. Besides decreasing the defaulter 
rate, we recommend for treatment of M/XDR-TB in Estonia a combination 
therapy with the duration of ≥20 months and with a higher rather than a 
lower number of SLDs during the intensive phase, as well as during the 
continuation phase. 
 
 The M/XDR-TB recurrence in Estonia was 8.5%. Males, persons of foreign 
ethnicity and those who were previously treated for TB or M/XDR-TB were 
at high risk for M/XDR-TB recurrence. The risk factors for increased all 
cause and TB mortality included as well the factors of male sex and foreign 
ethnicity besides higher age and lower level of education. More attention 
should be directed to persons of foreign ethnicity, as they are at higher risk 
of disease recurrence as well as all cause and TB mortality. The trends for 
international migration suggest that the proportion of foreign immigrants 
will increase in the forthcoming years, attracted by the increasing national 
wealth of Estonia. A more comprehensive immigration policy, considering 
the health issues, including TB, should be developed in Estonia. 
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8. FUTURE RESEARCH 
1. Evaluation of the effectiveness of the treatment of the M/XDR-TB patients 
with the novel drugs compared to the SLDs used in our studies up to now. 
 
2. For further evaluation of the performance of the NTP, assessment of overall 
and cause-specific mortality among TB and M/XDR-TB patients in 
comparison with a population group matched for socio-economic status. 
 
3. Evaluation of the actual problem of alcohol abuse and tobacco smoking 
among TB and M/XDR-TB patients in relation to 1) the general population 
and 2) to a population group matched for socio-economic status. 
 
4. Assessment of the quality of the TB-related care provided to the foreign 
born in comparison to Estonian-born persons. 
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SUMMARY IN ESTONIAN 
Tuberkuloos Eestis rõhuasetusega ravimresistentsele tuberkuloosile:  
koguhaigestumus, korduvhaigestumus ja suremus 
Tuberkuloos (TB) on nakkushaigus, mille tekitaja on peamiselt õhu kaudu leviv 
Mycobacterium tuberculosis. Peamine nakkusallikas ja nakkuse levitaja on 
baktereid eritav ehk nn lahtist TB-d põdev inimene. Pärast nakatumist püsib 
10%-ne eluaegne risk haigestuda TB-sse (1). 
Maailma Terviseorganisatsiooni (MTO) andmetel haigestus 2011. aastal TB-
sse 8,7 miljonit ja suri 1,4 miljonit inimest (2). Enamik juhtudest diagnoositi 
Kagu-Aasias, Vaikse ookeani lääneosas ja Aafrikas (2). 
Inimese immuunpuudulikkuse viirus (HIV) on üks peamisi TB-sse haigestu-
must soodustavaid tegureid. 2011. aastal oli kogu maailmas ligi 13% TB-hai-
getest HIV-infitseeritud, neist enamik Aafrikas. Samal aastal suri TB-sse 0,99 
miljonit inimest ja lisaks veel 0,43 miljonit HIV-koinfitseeritud TB-haiget (2). 
Viimastel aastakümnetel on kogu maailmas tõusnud haigestumus ravim-
resistentsesse TB-sse. Multiresistentne TB (MDR-TB) on TB vorm, mille puhul 
M. tuberculosis pole tundlik kahe kõige efektiivsema TB- ravimi, isoniasiidi ja 
rifampitsiini suhtes (2). Eeldatakse, et igal aastal haigestub maailmas ligikaudu 
630 000 inimest MDR-TB-sse. MDR-TB põhjuseks peetakse ebaregulaarset, 
ebapiisava annuse ja vale kombinatsiooniga ravimite kasutamist. 2011. aastal 
oli kokku 27 riiki, kus MDR-TB-haigete osakaal kõikide TB-haigete seas ületas 
6%, kahjuks oli Eesti üks neist (2). Lisaks MDR-TB-le on levimas nn eriti 
resistentne TB vorm (XDR-TB), mille puhul on haigustekitaja M. tuberculosis 
resistentne lisaks isoniasiidile ja rifampitsiinile veel vähemalt ühele fluorokino-
loonile ja vähemalt ühele teise rea süstitavale TB-ravimile (3). 2011. aasta 
lõpuks teatasid 84 riiki, nende seas Eesti, XDR-TB haigusjuhtude esinemisest. 
Eeldatakse, et ligikaudu 9% kõikidest MDR-TB-haigetest põevad XDR-TB-d, 
mis võrdub ligikaudu 58 500 haigusjuhuga (4). 
MTO eesmargiks maailmas on saavutada aastaks 2015 uute haigete ravi 
efektiivsus 90% ja MDR-TB juhtude ravi efektiivsus 75% (5). See eeldab 
õigeaegset TB ja M/XDR-TB diagnoosimist ning kohest efektiivset ravi. Ravi 
efekti hinnatakse nii vahetult ravikuuri lõpus kui pikemas perspektiivis, mille 
puhul on haiguse taaspuhkemine üks olulisem näitaja. Maailmas oli 2010. aastal 
ravi alustanud uute haigete ravi efektiivsus 87%, kusjuures Aafrikas, kus on 
suur HIV-infitseeritud TB-haigete osakaal, oli see 82%. Seevastu Euroopas, kus 
MDR-TB-haigete osakaal on maailma suurim, oli ravi efektiivsus vaid 67% (2). 
Multiresistentsete haigusvormide ravitulemus on ravimite madalama efektiiv-
suse, tugevate kõrvaltoimete ja pikema ravikestuse tõttu halvem võrreldes 
ravimtundliku TB-ga (3). Nii oli MDR-TB-haigete ravi efektiivsus maailmas 
48%, kuid XDR-TB-haigetel ainult (33%) (2). 
2008. aastal avaldatud süstemaatiline ülevaade järgi retsidiveerub haigus 
ravimtundlike haigete puhul 014% juhtudest (8). HIV-infitseeritud TB-haigetel 
esineb TB retsidiive sagedamini kui mitteinfitseeritute seas (8,2 vs 2,2/100 
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inimaasta kohta) (9). MDR-TB retsidiveerumist käsitlevaid uuringuid on aga 
tehtud vähe. Lõuna-Koreas ravitud haigetel esines näiteks kaheaastase jälgi-
misaja jooksul retsidiive 4,4%-l patsientidest, kes kasutasid individualiseeritud 
raviskeeme (10).  
On teada, et TB, HIV-nakkus, suitsetamine ja alkoholi kuritarvitamine on 
kujunenud epideemiateks ning omavahel tihedalt seotuna (11) nad tõstavad TB-
sse haigestumise ja surmariski.  
Eestis hakkas TB- ja MDR-TB-haigestumus kasvama 1993. aastal, pärast 
Nõukogude Liidu lagunemist, mis ulatuslike sotsiaalsete ja majanduslike muu-
tuste näol tõi kaasa nn üleminekušoki. Eestis 1994. aastal läbi viidud esimene 
ravimiresistentsuse uuring tuvastas MDR-TB 10,3%-l uutest TB juhtudest (13). 
1998. aastal jõudis TB-haigestumus Eestis haripunkti – 59,4 uut juhtu/100 000. 
Samal aastal, võitlemaks kasvava TB ja M/XDR-TB ohuga, kehtestati Eestis 
Riiklik TB-tõrje programm, mis juhindus MTO otseselt kontrollitava ravi-
strateegia (DOTS) printsiipidest: 1) valitsuse toetus TB-tõrje programmile; 2) 
prioriteet TB-juhtude passiivsele (haige pöördumisel) ja riskirühmades aktiiv-
sele avastamisele; 3) standarditud 6–8-kuulise otseselt kontrollitava ravi 
skeemide kasutamine; 4) kõigi vajalike TB-ravimitega varustamise tagamine; 5) 
ühtne registreerimis- ja kontrollsüsteem. Seoses kõrge MDR-TB-sse haigestu-
muse ja kallite reservpreparaatide puudumisega taotles Eesti ühena esimesest 
viiest riigist MTO ja Peatage TB Partnerluse (Stop TB Partnership) MDR-TB 
komitee (GLC) luba järgida tollal uudset MDR-TB käsitlust ning võimalust osta 
hea kvaliteediga reservpreparaate alandatud hindadega. Üks käesoleva uuringu 
eesmärkidest oli hinnata eelpool mainitud esimese MDR-TB projekti ravi 
efektiivsust. 
Eestis ja kogu maailmas varitseb oht, et kahe samaaegselt laieneva ja 
teineteist õhutava epideemia, M/XDR-TB ja HIV koosmõju tulemusena väljub 
TB- ja M/XDR-TB-epideemia kontrolli alt. Pärast üle 10 aastat kestnud TB-
programmi on oluline analüüsida TB-sse ja M/XDR-TB-sse haigestumust ja 
suremust ning neid mõjutavaid tegureid, et tõhustada TB-vastast tööd ning 
pakkuda tulemusrikkamat patsientide ravi. 
 
 
UURINGUTE EESMÄRGID 
Uuringute üldine eesmärk oli hinnata TB ja M/XDR-TB mõju TB haigestu-
musele, korduvhaigestumusele ja suremusele ning määratleda surma põhjused 
TB ja M/XDR-TB-haigetel.  
 
Töö alaeesmärgid olid:  
 
Töö osa I Määratleda kitsaskohad ülemaailmses TB-tõrjes jõudmaks 
rahvusvaheliselt seatud eesmärkideni globaalsel tasandil.  
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Töö osa II Hinnata üleriigilise TB käsitluse ja reservpreparaatide kasutuse 
efekti kopsu-TB ja spetsiifiliselt kopsu-MDR-TB haigestu-
musele arvestades Eesti majandusnäitajate mõju ning HIV-
infektsiooni ja TB koosesinemist. 
 
Töö osa III Hinnata esimese MTO MDR-TB komitee projekti (GLC) 
raames ravitud MDR-TB- and XDR-TB-haigete ravi efektiiv-
sust ning hinnata korduvhaigestumise riskitegureid Eestis. 
 
Töö osa IV Hinnata ravimtundlikku TB-d ja MDR-TB-d põdevate patsien-
tide üld- ja põhjusomast suremust võrreldes seda Eesti kogu-
rahvastiku omaga nii pärast diagnoosimist kui ka pärast edukat 
ravi. 
 
 
PATSIENDID JA MEETODIKA 
Töö osa I võttis kokku erialakirjanduse andmed leidmaks kitsaskohti ülemaa-
ilmse TB-tõrje tarvis. 
Töö osa II hindas TB ja MDR-TB haigestumust ning sisemajanduse kogu-
produkti, reservrea preparaatide ja HIV-nakkuse olemasolu efekti haigestu-
misele Eestis. Sellesse uuringusse (II) kaasati kõik ajavahemikus 
01.01.199831.12.2006 diagnoositud kopsu-TB esmased haiged ja retsidiivid.  
M/XDR-TB-haigete ravi efektiivsuse hindamiseks (III) kaasati uuringusse 
esimese MTO MDR-TB komitee projekti raames ravitud MDR-TB- ja XDR-
TB-haiged, kes olid diagnoositud nimetatud TB vormidega ajavahemikus 
1.08.200131.07.2003. Uuringust arvati välja haiged, keda oli teise rea TB-
ravimitega ravitud alla ühe kuu. Korduvravijuhtude esinemise hindamiseks 
moodustati kaks haigete rühma: 1) kohort 1, kuhu hõlmati kõik diagnoositud 
haiged ja 2) kohort 2, kuhu kuulusid ainult edukalt ravitud haiged.  
Hindamaks TB ja MDR-TB patsientide üld- ja põhjusomast suremust 
võrreldes kogurahvastikuga (IV), kaasati uuringusse kõik esmaselt hingamis-
elundite TB-sse haigestunud patsiendid ajavahemikus 01.01.200231.12.2009. 
Haigete suremust ravi jooksul ja samuti pärast edukat ravi hinnati eraldi 
kohordis 1 ja kohordis 2.  
 
Andmekogumine ja statistiline andmetöötlus 
Uuringu andmebaas põhines Eesti Tuberkuloosi Registri ning Tartu ja Tallinna 
tuberkuloosi ja mükobakterioosi laborite andmebaasidel (IIIV). Andmed aasta 
keskmise rahvaarvu kohta saadi Eesti Vabariigi Statistikaametist; andmed HIV-
infitseerituse kohta Tervise Arengu Instituudist ning andmed surmade kohta 
Eesti surmaregistrist rahvusvahelise haiguste ja nendega seotud tervise-
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probleemide statistilise klassifikatsiooni 10. versiooni (RHK-10) järgi. Andmed 
sisemajanduse koguprodukti kohta saadi Eurostatist.  
Andmete statistiliseks analüüsiks (II, III) kasutati tarkvarapaketi SPSS®, 
versiooni 17.0; töö osa IV puhul kasutati tarkvara Visual FoxPro 6.0 ja Stata 10. 
Analüüsiti vaid täielike andmetega haigusjuhte. 
Trendi hindamiseks kasutati Cochrani-Armitage`i trendifunktsiooni ja 
lineaarset regressioonanalüüsi analüüsimaks TB-vastaste reservpreparaatide, 
HIV-infektsiooni ning sisemajanduse koguprodukti efekti TB ja M/XDR-TB 
haigestumusele. 
Elulemust ja korduvhaigestumust analüüsiti Kaplani-Meieri meetodiga, 
kusjuures rühmadevahelise erinevuse testimiseks kasutati Breslow’i testi. 
Riskitegurite hindamiseks (III) kasutati Cox’i regressioonanalüüsi meetodit 
Wald’i statistiliste kriteeriumitega.  
Standarditud suremusmäär (SMR) arvutati eraldi meestele ja naistele, selle 
korral jagati tegelik surmajuhtude arv eeldatava surmajuhtude arvuga. Eeldatav 
surmajuhtude arv arvutati korrutades soo- ja vanuse järgi esitatud inimaastad 
vastavate Eesti rahvastiku suremuskordajatega. Eraldi analüüsiti suremust TB 
tagajärjel ja suremust muudel põhjustel kahe perioodi kohta: 20022006 ja 
20072011. SMR-idele arvutati 95% usaldusvahemik (95% CI) eeldades Pois-
son’i jaotust. Mitmemõõtmelist Poisson’i regressiooni mudelit kasutati hinda-
maks vanuse, hariduse, rahvuse ja MDR-TB efekti suremusele.  
 
 
UURINGUTE PEAMISED TULEMUSED 
Töö osa I 
2003. aastaks oli ülemaailmne TB ravi edukus 82%, mis oli lähedal globaalsele 
eesmärgile 85%. Siiski, Aafrikas oli see vaid 72% ja Euroopas 75%. Peamised 
kitsaskohad TB-vastases võitluses rahvusvaheliselt seatud eesmärkideni jõud-
misel oli kõrge MDR-TB-haigestumus Euroopas ja kõrge HIV-infektsiooni 
haigestumus Aafrikas (130). 2004. aastal kuulus Eesti kümne kõige kõrgema 
MDR-TB haigestumusega riigi hulka maailmas, s.o riikide hulka, kus MDR-TB-
levimus on üle 6,5% kõikidest TB juhtudest. Konkreetselt oli Eestis MDR-TB-
haigestumus esmaste TB-haigete seas 12,2%. Lisaks Eestile kuulusid esiküm-
nesse veel: Kasahstan (14,2%), Tomski oblast Vene Föderatsioonis (13,7%), 
Karakalpakstan Usbekistanis (13,2%), Leedu (9,4%) ja Läti (9,3%) (130, 145). 
Detsembriks 2006 oli käivitunud 53 GLC egiidi all olevat projekti MDR-TB 
käsitluseks 42 riigis. Tänu GLC projektidele said riigid võimaluse osta soodus-
tusega hea kvaliteediga reservrea preparaate MDR-TB-haigete raviks. Eesti oli 
üks esimesest viiest GLC egiidi all tegutsevast MDR-TB-projektist, esimese 84 
MDR-TB-haige ravi efektiivsus oli 51.2% (43/84). Viie esimese MTO MDR-
TB-projekti (Eesti, Läti, Peruu, Filipiinid ja Tomsk Vene Föderatsioonis) 
raviedukus koondarvestuses oli 77% esmajuhtude ja 69% korduvravijuhtude 
puhul (61).  
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Töö osa II 
Uuringusse kaasati 5196 esmast kopsu-TB juhtu ja retsidiivi, kellest 4086 
(71,7%) olid mehed. Patsientide vanuse mediaan oli 45,9 aastat. HIV-infit-
seerituse andmed olid teada 3033 isikul (58,4%), neist 132 (4,4%) olid HIV-
positiivsed. Ravimtundlikkus oli määratud 3862 isikul (74,3%), kellest oma-
korda 760 (19,7%) põdesid MDR-TB-d. Viimastest omakorda 95-l (17,1%) oli 
XDR-TB.  
Ajavahemikul 1998–2006 vähenes TB-haigestumus 50,2-lt juhult kuni 32,7-
ni 100 000 inimese kohta. TB-tõrje programmi käivitumise järgsel 1998. aastal 
vähenes haigestumus keskmise kiirusega 3,3 juhtu 100 000 inimese kohta aastas 
(langus keskmiselt 7,02% aastas, P=0,007). Sama perioodi jooksul kahanes 
M/XDR-TB haigestumus vastavalt 6,7-lt 3,5-le. Keskmine aastane haigestumise 
langus oli seega 1,7 juhtu 100 000 inimese kohta aastas ehk 5,5% aastas 
(P=0,008). 
Vaatlusperioodi ajal suurenenud sisemajanduse koguprodukt mõjutas TB ja 
M/XDR-TB-haigestumuse langust (vastavalt P<0,001 ja P<0,001). TB-vastaste 
reservpreparaatide olemasolu alates 2002. aastast kiirendas haigestumuse 
langust. Samas tõusis HIV-infitseeritute TB-haigete osakaal, mis mõjutas TB 
haigestumust olulisel määral negatiivselt (vastavalt P<0,001 ja P=0,001). 
Ajavahemikul 1998–2006 uuringusse kaasatud mitte-MDR-TB-haigete ravi 
efektiivsus tõusis 72,7%-lt 77,4%-le (P=0.009), kuid MDR-TB-haigetel ravi 
efektiivsus seevastu alanes 54,8%-lt 51,1%-le (P=0,018). XDR-TB-haigete ravi 
koondtulemus oli 47,7%, kuid vähese arvu uuritavate tõttu polnud võimalik 
ajatrendi statistiliselt hinnata. 
 
Töö osa III 
Uuringus osales 211 ajavahemikul 01.08.200131.07.2003 diagnoositud MDR-
TB-haiget, sealhulgas 43 XDR-TB-haiget. Haigete jälgimine kestis kuni 
31.12.2010 või kuni järgmise haiguse episoodi alguse, surma või lahkumiseni 
Eestist. Keskmine vanus oli 42,9 aastat. Uuritavatest 154 (73,0%) olid mehed ja 
172 (81,5%) eestlased. Kokku 197 haiget (93,4%) olid testitud HIV-nakkuse 
suhtes ja neist 5 (2,5%) olid HIV-positiivsed. 
Edukas ravitulemus saavutati kokku 129 (61,1%) haige puhul, MDR-TB-
haigete puhul oli ravi efektiivsus 63,1% ja XDR-TB-haigete puhul 53,5%. 
Edukalt ravitud haigete ravikestus jäi 6,1 ja 53,7 kuu vahele, keskmine 
ravikestus oli 19,8 kuud. Edukalt ravitutest 11 isikut (8,5%) haigestus uuringu 
jooksul TB-sse teistkordselt. Kokku 47 isikut (22,3%) katkestas ravi, 18 (8,5%) 
osutusid ebaedukalt ravituteks ja 17 (8,1%) surid. 
Kõiki haigeid arvesse võttes oli keskmine jälgimisaeg 98,1 kuud, mille 
jooksul 38 haiget (18,0%) suri TB-sse. Kumulatiivne haigusvaba aeg oli pikem 
MDR-TB-haigetel võrreldes XDR-TB-haigetega. Taashaigestumist esilekutsu-
vad riskitegurid olid: meessugu, mitte-eesti rahvus, eelnevalt põetud TB, ravi 
alustamisel TB-bakterite suhtes positiivse röga äige olemasolu, ravimresistent-
sus suurema hulga ravimite suhtes, resistentsus kahe reservrea aminoglükosiidi 
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või tsüklilise peptiidi suhtes ning eelnimetatud preparaatide ja lisaks strepto-
mütsiini puudumine raviskeemist. Suurema tõenäosuse selleks, et haigus ei 
retsidiveeruks, andis para-aminosalitsüülhappe lisamine raviskeemi ja suurema 
arvu ravimite kasutamine järelravifaasis. XDR-TB-haigete puhul olid riski-
tegurid samad, ent lisaks oli retsidiveerumise vältimiseks oluline ofloksatsiini 
lisamine raviskeemi ja ravimite mitteärajätmine kõrvaltoimete tõttu.  
Edukalt ravitud 129 haigest ei erinenud M/XDR-TB- ja mitte-MDR-TB-
haiged omavahel haiguse retsidiveerumise tõenäosuse poolest. Ainsaks teguriks, 
mis mõjutas TB kordumist edukalt ravitute puhul, oli TB põdemine enne 
uuringu algust. 
 
Töö osa IV 
Ajavahemikul 01.01.200231.12.2011 kaasati uuringusse 2449 esmast 
hingamiselundite TB-i põdevat haiget vanuses 2564 aastat, neist 1777 (72,5%) 
olid mehed ja 674 (27,5%) naised. HIV-infektsiooni suhtes oli testitud 2210 
isikut (90,2%), kellest 131 (5,9%) olid HIV-positiivsed. Keskmine vanus oli 
meestel 44,3 aastat (standardhälve (SD) 10,0 aastat) ja naistel 42,2 aastat (SD 
10,9 aastat). Rohkem kui pool haigetest (54,2%) olid eestlased. Enamik (93,1%) 
olid kesk- ja madalama haridusega ning põdesid mitte-M/XDR-TB-i (64,4%). 
Kokku 2013 haiget (82,2%) osutusid edukalt ravituteks, kuid samas 182 (7,4%) 
surid TB-ravi ajal. Haigete jälgimine kestis kuni 31. detsembrini 2011 või kuni 
järgmise haigusepisoodi alguse, surma või lahkumiseni Eestist. Kogu uurimis-
perioodi jooksul suri 661 haiget (27,0% uuringusse kaasatutest). Diagnoositud 
1775 mehest suri 535 (8858 inimaastat; keskmine jälgimisaeg 5,0 aastat), SMR 
oli 5,3 (95% CI 4,855,75) ja diagnoositud 674 naisest suri 126 (3806 inim-
aastat; keskmine jälgimisaeg 5,6 aastat), SMR oli 10,00 (95% CI 8,2511,74). 
TB tõttu suri 137 meest ja 29 naist.  
Nii meestel kui naistel olid surmapõhjused nii pärast diagnoosimist kui ka 
pärast edukat ravi sarnased. Kõrge oli suremus HIV-nakkuse tõttu. Tähele-
panuväärne oli kõrge suitsetamisest ja alkoholi kuritarvitamisest tingitud sur-
made osakaal võrreldes kogurahvastikuga, seda nii pärast TB-sse haigestumist 
kui ka pärast eduka TB-ravi lõppu. Meeste puhul olid täiendavad riskitegurid 
mitte-eesti rahvus, madalam haridus, kõrgem iga ja M/XDR-TB esinemine. 
Pärast edukat ravi ei erinenud MDR-TB-haiged suremuse poolest mitte-MDR-
TB-haigetest. Naiste puhul olid surma riskitegurid samad, mis meestel, välja 
arvatud haridus, mis naistel ei osutunud surma riskiteguriteks. 
 
 
JÄRELDUSED 
 M/XDR-TB on peamiseks takistuseks jõudmaks TB-vastases võitluses nii 
Eestis kui globaalsel tasandil rahvusvaheliselt seatud eesmärkideni. Antud 
töö põhjal järeldame, et Eestis on TB ja M/XDR-TB kõrge haigestumus 
tihedalt seotud HIV-infektsiooniga. TB- ja M/XDR-TB-haigete kõrgem 
suremus Eestis on mõjutatud sellistest teguritest nagu suitsetamine ja 
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alkoholi liigtarvitamine, madalam haridustase ja sotsiaalne tõrjutus, mis 
omakorda on seotud vaesusega. Selleks, et Eestis parandada M/XDR-TB 
ravi edukust ja tõhustada TB ja M/XDR-TB tõrjet üldisemalt, peavad TB-ga 
seotud raviteenused olema suunatud kõikide eelmainitud kitsaskohtade 
vastu.  
 
 Alates 1998. aastast, samaaegselt Eesti Tuberkuloositõrje programmi 
kehtestamisega ja käsikäes üleriigilise M/XDR-TB raviks vajalike reservrea 
preparaatide olemasoluga ning sisemajanduse koguprodukt suurenemisega, 
on TB ja M/XDR-TB haigestumus Eestis vähenenud. Samas on HIV-
infitseeritus viimase kümnendi jooksul tõusnud ja eelduste kohaselt jätkab 
tõusu veel mõne aja jooksul. Vältimaks kahe epideemia, HIV ja TB, eriti 
aga HIV ja M/XDR-TB koosmõju, on oluline senisest kiiremas tempos 
alandada TB- ja M/XDR-TB-haigestumust, mis praegu alaneb vastavalt 
7,07% ja 5,5% aastas.  
 
 Senisest suuremat tähelepanu on vaja osutada M/XDR-TB-juhtude varasele 
diagnoosimisele ja samas parandada ravitulemusi, et saavutada MTO poolt 
soovitatud 75%-ne ravi efektiivsus. Esimese GLC soovituste kohaselt 
ravitud M/XDR-TB-haigete ravi edukus oli vaid 61,1%, nii madal oli see 
peamiselt ravikatkestajate tõttu. Meie uurimistööle tuginedes soovitame 
lisaks ravikatkestuste vähendamisele kasutada Eestis M/XDR-TB-haigete 
puhul kombinatsioonravi pigem suurema kui väiksema arvu TB-ravimitega. 
Ravi on soovitatav jätkata vähemalt 20 kuud.  
 
 M/XDR-TB-korduvhaigestumus oli Eestis 8,5%. Meestel, mitte-eestlastel ja 
eelnevalt TB-d põdenutel on suurem tõenäosus korduvalt haigestuda 
M/XDR-TB-sse. Samas on TB- ja M/XDR-TB-haigete kogusuremuse ja 
TB-tingitud surma risk suurem meestel ja mitte-eestlastel nagu ka mada-
lama haridustasemega ja vanematel isikutel. Rohkem tähelepanu tuleb 
osutada mitte-eestlastest TB-d põdevatele isikutele, sest neil esines rohkem 
korduvhaigestumist. Samuti oli mitte-eestlastest TB-d ja M/XDR-TB-d  
põdevatel isikutel võrreldes kogurahvastikuga kõrgem nii kogusuremuse 
risk kui ka TB-st tingitud surmarisk. Jälgides rahvusvahelisi rändetrende 
saab oletada, et seoses sisemajanduse koguprodukti suurenemisega võib 
mitte-eestlastest isikute osakaal lähiaastatel suureneda. Vajalik on välja 
töötada Eestis terviklik, ka immigrantide tervise ja TB-ga tegelev 
programm. 
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